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Abstract 
Amyloid protein aggregation is notorious for its association with many devastating 
human diseases such as AIDS, cancer, Alzheimer's disease, and prion diseases. Scientists have 
made significant progress in designing modulators which prevent amyloid formation and provide 
potential therapeutics for amyloid-related diseases. Recently, extensive studies indicate that the 
elusive oligomeric intermediates, rather than the most visible amyloid fibrils, are the cause of 
cytotoxicity in amyloid aggregation. However, the rational design of synthetic modulators that 
specifically target the toxic oligomer intermediates and regulate the final shape and size of 
amyloid assemblies remains a challenge. Breakthroughs in this area provide insight and 
understanding for the toxic oligomer intermediates and the mechanism of amyloid protein 
aggregation. The fundamental studies on molecular level also provide the potential foundation 
for promising solutions to investigate amyloid-related diseases.  
This dissertation describes a new class of rationally designed polymeric modulators 
which specifically target amyloid  oligomers and control amyloid aggregation. Chapter 2-3 
focus on the design of series of polymer-peptide conjugates which redirect A fibrillar assembly 
by stabilizing A oligomers into structurally well-defined discrete nanostructures. The 
modulatory effect was achieved by taking advantages of nucleation-dependent mechanism of A 
aggregation. We investigated the influence of multivalency and specificity of molecular 
structures and optimized the A modulatory effect by tuning molecular weights of polymers, as 
well as the loading ratio and the sequences of the attached A recognition peptides. Chapter 4 
describes the extended application of polymer-peptide conjugates as fibril breakers to dissociate 
preformed A fibrils, and the dissociation rate is dependent on the molecular weight of 
conjugates. Chapter 5 reports the design of polyethylenimine-perphenazine conjugates as dual 
modulators which accelerate the formation of A prefibrillar intermediates and inhibit the 
following fibrillation. The above polymeric conjugates are proved to detoxify A oligomers and 
the results of MTT cell viability assays are summarized in Chapter 6. Our molecular design may 
thus represent a prototype of multivalent macromolecules that control the amyloid fibrillar 
assembly via a nucleation-dependent mechanism. It remains to be seen if this design concept is 
broadly applicable to the control of other molecular self-assembly process. 
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Chapter 1: Introduction 
1.1 Overview of Pathogenic Amyloid Peptides 
Amyloid proteins are a class of proteins that enter the so-called amyloid state, in which 
they form elongated and unbranched fibrils, consisting of β-sheet secondary structure. The 
aggregation process of amyloid proteins are associated with more than 20 lethal human diseases, 
including amyloid  peptide (A) with Alzheimer’s disease, islet amyloid polypeptide with 
diabetes type II, and prion protein with the spongiform encephalopathies.
1,2
 Amyloid  is one of 
the most notorious amyloid proteins for its association with Alzheimer’s disease.  
Alzheimer’s disease is a neurodegenerative disease that causes 60% to 70% of dementia 
cases, characterized by progressive loss of memory and other cognitive functions such as 
problem with language, disorientation, and behavior issues.
3
 As the disease advances, the 
patients often withdraw from family and society and ultimately the patients die in a helpless state. 
AD patients require resource-intensive care and it is an enormous emotional and financial burden 
on patients, their families, and society. In 2015, there are 5.4 million Americans living with AD 
and the payments for care are estimated to be $604 billion in the world.
4,5 
There are various pathological markers of Alzheimer’s disease, including large numbers 
of amyloid plaques surrounded by neuros containing neurofibrillary tangles, vascular damage, 
and neuronal cell loss.
6
 In 1907, Alois Alzheimer first proposed the biomarkers of AD, which are 
the accumulation of amyloid β peptide and phosphorylated tau.7,8 However, the role of these 
markers in the etiology of the disease is controversial.  
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Figure 1.1 Dynamic events as a basis for use of biomarkers. MCI: mild cognitive impairment.
9
 
(Reprinted with permission from ref 9. Copyright © 2010 Elsevier.) 
 
In recent years, the amyloid cascade hypothesis for AD has been very influential in the 
field.
10
 This hypothesis was first proposed by John Hardy and Gerald Higgins claiming that the 
deposition of Aβ peptide is the cause of AD pathology and the above markers are direct results 
of this deposition.
11
 Amyloid precursor protein (APP) is a transmembrane protein. In normal 
brain, APP is cleaved at residue 15-17 within Aβ sequence by APP secretase. Thus the generated 
peptide fragments do not contain intact Aβ and cannot form the amyloid deposition. In the AD 
patients’ brain, the Aβ peptide (Mn~4 kDa) is produced from APP via sequential scission by the 
enzymes β- and γ-secretase (Fig. 1.2).11 γ-secretase cleaves at C-terminal at different positions, 
generating a variety of peptides with different length, including Aβ43, Aβ42, Aβ40, Aβ38, and 
Aβ37.
12,13 
The resulting intact Aβ is a heterogeneous mixture of peptides having different 
solubility, stability and toxic properties. Aβ peptides precipitate to form amyloid and cause cell 
death and other hallmarks of AD.   
The amyloid cascade hypothesis has been modified over years due to the lack of 
correlation between dementia and Aβ plaque accumulation, both amount and location.14,15 The 
insoluble Aβ fibrils found in amyloid plaques and monomeric Aβ are less pathogenic than 
soluble, nonfibrillar assemblies of Aβ such as Aβ dimers, trimers, and larger oligomers.16,17 The 
intermediates oligomers form between the soluble Aβ monomers and insoluble Aβ fibrils, but the 
exact molecular composition and structures of these oligomers are still elusive. The dynamic 
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nature of these species and the poorly understood mechanisms of toxicity make this topic 
particularly controversial in the field. 
 
Figure 1.2 Amyloid cascade hypothesis. (Reprinted with permission from ref 18. Copyright 
© 2011 Nature Publishing Group) 
1.2 Structures and Toxicity of A Oligomers 
Various types of oligomeric species have been identified, such as protofibrils, paranuclei, 
globulomers, and Aβ-derived diffusible ligands (ADDLs).19 Globulomers are stable globular 
oligomers that are prepared by careful preparation methods starting from Aβ-monomers. Kayed 
and co-workers used hexafluoroisopropanol (HFIP) to disperse Aβ into monomers and then 
evaporated HFIP in a controlled manner to prepare oligomers.
20,21
 This solution was then 
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redissolved in NaOH and diluted in PBS buffer.
22,23
 Electrophoresis in denaturing gels revealed a 
spectrum of oligomers including dimers, trimers, tetramers, pentamers, and higher-order 
oligomers up to 24-mers.
24
 ADDLs are mixtures of Aβ monomer and heterogeneous “higher n” 
oligomers.
25,26
 These “higher n” oligomers are structures that larger than hexamer or 
globulomers. The observation of these oligomeric structures depends on how synthetic Aβ is 
prepared and incubated. The major natural and in vitro-generated A oligomers and their toxicity 
were summarized in Table 1.1.
27 
Table 1.1 Major soluble A oligomers and deleterious effects associated with them. 
Species Structure Biological Effects 
A-derived diffusible ligands 
(ADDL)
28-30 
3–24-mer 
Major component, 17 kDa 
(tetramer) 
Globular structures, 2–5-nm 
height 
Cytotoxicity in primary neurons 
(micromolar concentration) 
Cognitive impairment in mice 
 
A*5631,32 12-mer 
Globulomers 
56 kDa 
No cytotoxicity 
Cognitive impairment in rats 
(micromolar concentration) 
AO33-35 15–20-mer 
Spherical vesicles 2–5 nm 
Cytotoxicity in human neuronal 
cultures (5 μM) 
A42 and A42:40 (3:7) 
synthetic oligomers
36 
-sheet enriched 
Transient on-pathway species 
 
Cytotoxicity in primary neurons 
(micromolar concentration) 
Memory deficiency in mice 
A42CC protofibrils37 Intramolecular disulfide bond 
stabilized antiparallel 
-sheet–based structure that does 
not propagate into fibrils 
Caspase-3 activation in human 
neuroblastoma cells 
 
Annular protofibrils (APF)
38 
Form pores,  
11–14-nm outer diameter; 2.5–4-
nm inner diameter 
36-mer, 155 kDa 
Hypothesized to cause Ca
2+
 
overload and cytotoxicity 
(micromolar concentration) 
 
SDS-stable dimers and trimers 
isolated from cell culture 
medium
39-41 
6-, 8- and 12-kDa assemblies No cytotoxicity 
Cognitive impairment in mice 
(low-nanomolar 
concentrations) 
SDS-stable brain-derived dimers 
and synthetic dimers
42-44
 
8–12-kDa assemblies 
3–4-nm height 
No detectable secondary 
structure 
No cytotoxicity to primary 
neurons (micromolar 
concentration)  
but toxic to neurons cultured with 
microglia 
SDS-stable amylospheroids 
(ASPD; synthetic 
or brain-derived)
45-47 
10–15-nm spherical A 
assemblies 
32–150-mers 
Cytotoxicity in neurons 
(highpicomolar to low-
micromolar concentration) 
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Many of the studies investigating the toxic oligomers are based on the assumption that 
the oligomers are stable structures that interact specifically with receptors (Figure 1.3).
48-52
 
However, the oligomers prepared in different labs under different conditions are difficult to 
replicate and compare. The studies based on the precise and specific biological mechanisms 
might thus be very misleading. According to the vast literatures in this area, it is clear that no 
single mechanism explains all aspects of Aβ oligomer toxicity. It is believed that aggregation 
state, amphiphilicity, and the organization of hydrophobic residues within an oligomeric 
assembly all affect toxic effects of such oligomers.
27
 Thus, instead of the existence of specific 
Aβ toxic oligomers for receptors, it is more likely that Aβ peptides, a mixture of various 
oligomers and aggregates, will exert multiple effects by binding to membrane proteins, targeting 
membrane lipids, causing oxidative stress and changing membrane dielectric properties and ion 
permeability in non-specific ways (Figure 1.3).
27 
 
Figure 1.3 Multiple effects of A oligomer-initiated neurodegenerative cascade according to the 
amyloid hypothesis.  
Previous literatures also discussed a more generic type of toxicity, which suggest that the 
Aβ aggregation process itself from soluble monomers and oligomers to fibrils is sufficient to 
cause cell death.
53
 This result suggests that the cytotoxicity is not caused by any particular Aβ 
species but the nucleation-dependent dynamic fibrillation process itself. It was indicated that the 
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exposure of “toxic surfaces” derived from the abnormally folded peptides subsequently interact 
with other molecules.
54
 The hypothesis of a dynamic fibrillation-associated toxicity is compatible 
with many of the observations in the literatures with regard to the Aβ assembly process, but the 
mechanism of toxicity remains unclear in this model. 
1.3 Conformation and Structures of A Fibrils 
The morphology of amyloid fibrils are usually unbranched fibrils only a few nanometers 
in diameter and micrometers in length. The mature fibrils consist of multiple protofilaments that 
twist around each other, and each of the protofilaments adopts a cross- structure, in which -
strands form continuous hydrogen-bonded -sheets that run along the length of fibrils.55,56 The 
cross- structure originates from the propensity of polypeptide chains to form backbone 
hydrogen bonding (Figure 1.4a). The lateral packing of -sheets results from the interactions 
between side chains of amino acids.
57
 The formation of continuous array of hydrogen bonds 
provides great stability to the fibrils.
58
  
 
Figure 1.4 Amyloid structures exhibit a range of specific features and possess common 
characteristics. Representation of the 'cross-β' structure common to amyloid fibrils (a), the 
stability of the amyloid state is dependent on the protein concentration. At concentrations 
exceeding the critical value, a protein is more stable in the amyloid state than in its native state 
(b)
59
 (Reprinted with permission from ref 39. Copyright © 2014 Nature Publishing Group) 
A series of studies have been done to investigate the reason why the assembly of a large 
number of polypeptide chains should generate such high ordered structure.
60,61
 Previous 
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theoretical studies indicate that the inherent properties of polypeptide chains, including the local 
stiffness and the chirality of the -carbon atoms lead to the amyloid characteristics.62 The one 
dimensional cross- fibrils may be the most organized structure that can be formed by flexible 
polypeptide chains (Figure 1.4b).
63
 The uniform width of fibrils is the result of competition 
between the intrinsic tendency to form twisted structures and the increasing energy penalty due 
to the elastic deformation of thick filaments into twisted structures.
63
  
1.4 Kinetics of A Aggregation 
The kinetics study on amyloid aggregation is increasingly revealing the complex 
aggregation mechanism. However, the kinetics study has been highly challenging because of the 
difficulties in obtaining reproducible kinetic data and the nonlinear nature of the differential 
equations that describe the protein aggregation.
59
 In recent years, both experimental and 
theoretical progress show that these obstacles have been overcome, and the kinetics of amyloid 
fibril assembly have been widely studied. Amyloid aggregation proceeds via a nucleation 
dependent mechanism which is highly concentration dependent. In a typical nucleation 
dependent aggregation, a lag phase is observed before a rapid growth phase. If the total quantity 
of protein is limited, the growth phase is followed by an equilibrium phase when the aggregation 
rate decreases as a result of the depletion of the monomers that convert into fibrils. When 
monomers add to the ends of the fibrils, they adopt the cross-β conformation to match that of the 
peptides already present in the aggregate that hence function as templates.
64,65
 Vise versa, when 
pre-formed amyloid aggregates are added to a solution during its lag phase, the fibrils will grow 
rapidly, similar to the seeding phenomena in the crystallization.
66
 In summary, the fibrillation 
process of amyloid can be triggered by nucleation, templating or seeding from existing 
aggregates.  
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Figure 1.5 Kinetics of A aggregation. 
1.5 Current Modulators that Inhibit A Aggregation 
Although the mechanism of amyloid cytotoxicity is not clear, strategies to prevent 
amyloid formation have made significant progress and are even promising in designing new 
therapeutics.
67
 The previous literatures have not only shown some examples of how inhibition 
has been achieved in practice, but also shed light on further understanding of aggregation 
mechanism. The inhibition actions were employed by small or large molecules binding to 
different states of amyloid-forming intermediates. For example, protein engineering provides 
new binding proteins that sequester monomeric peptides from aggregation, small molecules and 
peptides are designed to inhibit aggregation or convert toxic oligomers to non-toxic species, and 
monoclonal antibodies have been developed to inhibit aggregation or clear amyloid aggregates.
67 
Many small molecules have been studied for their activity to influence Aβ-aggregation 
and reduce cytotoxicity. However, the design of small molecules which target amyloid assembly 
process is different from traditional drug design that targets a specific biomolecule, for example, 
an enzyme.
68
 The current small molecules are general inhibitors that interact with several 
different amyloid proteins. Such non-specific behavior is usually not a desirable property of drug 
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candidates and the interference with functional amyloid
69
 in humans may cause other 
complications for this strategy.
 
Peptide inhibitors use self-recognition elements. They are designed based on fragments of 
Aβ, which bind to the corresponding sequence in the native peptide but disrupt β-sheet 
formation.
70
 For instance, it has been demonstrated that the peptide based on central hydrophobic 
sequence of Aβ (KLVFFA) showed promises as self-recognition elements.71 The peptide 
inhibitors have modifications including charge, branching, D/L-isomer substitution, and 
counterion type that disrupt the amyloid fibrillation process.
72
 Another type of peptide sequence 
modification is via N-methylation of alternate residue, which disrupt self-assembly due to the 
presentation on one face of the β-strand of residues incapable of adopting the usual hydrogen-
bonding pattern. 
Antibody mediated inhibition and immunotherapy is another promising route. O'Nuallain 
and coworkers developed antibodies to Aβ amyloid fibrils, which recognize amyloid fibrils form 
a variety of different proteins.
73
 With emerging insight about the cytotoxicity of prefibrillar Aβ 
oligomers, many efforts have been made to develop antibodies that recognize conformational 
epitopes on oligomer species.
74
 Glabe and coworkers obtained A11 antibody which had selective 
binding to soluble Aβ oligomers, and their antibody also recognized and detoxified soluble 
oligomers of other amyloid proteins, suggesting that a common conformational epitope might be 
involved in cytotoxic mechanisms.
75 
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Chapter 2: Design and Synthesis of Polymer-Peptide Conjugates 
2.1 Introduction 
As introduced in Chapter 1, the design of modulators to prevent amyloid formation have 
shown some promises in developing new therapeutics for Alzheimer’s disease and shed light on 
further understanding of amyloid aggregation mechanism.
1
 The current modulators mostly fall 
into three categories, small molecule, peptide, and antibody.
2-4
 Since a new type of modulator 
might usher in breakthroughs of controlling amyloid aggregation and provide new design 
concepts, we asked whether there is an alternative approach. To the best of our knowledge, the 
concept of using a polymer to specifically bind amyloid protein has not been widely investigated. 
There are several advantages of a polymer scaffold compared to the previous modulators. First, 
polymer molecules are multivalent and the loading ratio of recognition elements that bind A is 
tunable. Second, the molecular size and architecture of polymers are easily adjusted to target 
different size and sequences of amyloid peptides. Third, polymers are nonimmunogenic and have 
longer plasma residence time compared to small molecules and peptides.
5
  
In this Chapter, we introduce the design and synthesis of polymer-peptide conjugates as a 
new class of modulators for Aβ aggregation. The polymer-peptide conjugates were synthesized 
by covalently conjugating multiple copies of Aβ recognition peptide onto a linear polymer 
backbone. The molecular weights were characterized by GPC and the molecular structures were 
characterized by NMR and FT-IR. 
2.2 Molecular Design of Polymer-Peptide Conjugates 
Since the size and shape of the final assemblies of Aβ are likely to be sensitive to both the 
structure of the nucleus and its kinetics of growth, we reasoned that molecular specific 
interactions at this stage presented an opportunity to manipulate and control the assembly 
process.
6
 Taking advantage of the slow nucleation stage, we propose that tailor-designed 
multivalent polymeric modulators which target oligomers can be employed to manipulate the 
aggregation before nuclei formation (Figure 2.1).  
16 
 
 
Figure 2.1 Cartoon representation of simplified Aβ protein aggregation without and with 
polymeric modulators. Polymeric modulators target Aβ oligomers to manipulate the aggregation 
before nuclei formation.  
For Aβ assemblies, it is widely accepted that during the nucleation phase of aggregation, 
metastable prefibrillar intermediates form through hydrophobic collapse with development of β-
sheet interactions between the central hydrophobic sequence Aβ17-21 (LVFFA).
7-9
 Taking 
advantage of this nature of Aβ aggregation, we designed and synthesized multivalent polymer-
iAβ5 (mP-iAβ5) conjugates in which LPFFD (iAβ5) was selected as the peptide fragment for the 
mPPCs, given its known binding with specificity to Aβ17−21.
10-12
 Poly(N-(2-hydroxypropyl)-
methacrylamide) (PHPMA) was selected as the polymeric scaffold due to its water solubility, 
zero net charge at neutral pH, and well-established synthesis.
13-15 
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Figure 2.2 Molecular design of polymer-peptide conjugates. The selection of peptide sequence 
and polymer backbone. 
2.3 General Synthetic Approach of Polymer-Peptide Conjugates  
The multivalent polymer-peptide conjugates were constructed by conjugating multiple 
copies of Aβ binding peptides onto a linear copolymer backbone 3 and the synthesis was shown 
in Scheme 1. By controlling the stoichiometry of polymers to peptides, the polymer-peptide 
conjugates with different peptide loadings were synthesized to accomplish different multivalency.  
The synthesis started with the copolymerization of N-(2-hydroxypropyl)methacrylamide 
(HPMA) 1 and N-hydroxysuccinimide methacrylate (NHSMA) 2 by reversible 
addition−fragmentation chain transfer (RAFT) polymerization to yield poly(HPMA-co-NHSMA) 
3 (Scheme 1).
16-17
 Due to the large difference in reactivity ratios of HPMA and NHSMA, it is 
impossible to synthesize copolymers with uniform composition by batch method. Instead, a 
semi-batch method was used to compensate for the large difference in reactivity ratios between 
two monomers, in which the more reactive NHSMA monomers were gradually added to the 
solution of HPMA.
18
 The molecular weight and polydispersity of 3 were determined by GPC 
(Figure 2.4), and the degree of polymerization was approximately 300. The thio-carbonyl end 
18 
 
group was removed to avoid side reactions in following steps.
19
 Peptide iAβ5 was conjugated to 
3 using different stoichiometric ratios, and all remaining active ester groups were then quenched 
by 1-amino-2-propanol to yield mP-iAβ5 conjugates 4.
20
 The consumption of NHS groups was 
confirmed by NMR. The polymer-iA5 conjugates were purified by Amicon filters to remove 
any unreacted peptides and other small molecule byproducts. Three mP-iAβ5 conjugates were 
prepared having on average 3, 7, and 12 mol % of iAβ5 per polymer chain (Figure 2.7, 2.9, 2.11). 
On the basis of the degree of polymerization, these conjugates have 9, 21, and 36 copies of iAβ5 
per chain, respectively. We use the notation mP-iAβ5-3%, mP-iAβ5-7%, and mP-iAβ5-12% to 
designate the peptide loading of these three conjugates. PHPMA polymer 5 was synthesized by 
quenching 3 with 1-amino-2-propanol to serve as a control for conjugates 4 (Figure 2.13).  
 
Scheme 2.1 Synthesis of mP-iA5 conjugates 4. 
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2.4 Experimental Details 
2.4.1 Materials and Methods 
Materials. N-hydroxysuccinimide methacrylate (NHSMA, 98%), 2-cyano-2-propyl 
benzodithioate (CIDB, >97%), dimethyl sulfoxide (DMSO, anhydrous, >99.9%), N, N’-
dimethylformamide (DMF, anhydrous, 99.8%), and tert-butanol (anhydrous, 99.5%) were 
purchased from Sigma-Aldrich and used as received. 2,2′-azobis(2-methylpropionitrile) 
perphenazine (AIBN, 98%) was purchased from Sigma-Aldrich and recrystallized before use. 1-
amino-2-propanol (94%) was purchased from Acros. N-(2-hydroxypropyl) methacrylamide 
(HPMA, 98%) was purchased from Polyscience. Amyloid  protein (A40) was purchased from 
GL Biochem Ltd. (Shanghai, China). Pentapeptide LPFFD (iA5) was purchased from American 
Peptide. Molecular biology grade water (ultrapure water) for ThT Assays was purchased from 
Corning. PBS buffer (100 mM) was purchased from Lonza (Cat No. 17-517Q, Lot No. 
0000447701).  All other solvents (HPLC or spectroscopic grade) were purchased from Sigma-
Aldrich or Fisher, and used as received. 
Nuclear Magnetic Resonance (NMR). 
1
H NMR spectra were obtained on a Varian Unity 400 
spectrometer in the School of Chemical Sciences NMR laboratory at the University of Illinois at 
Urbana-Champaign. Spectra were referenced to residual solvent peaks. Chemical shifts are 
expressed in parts per million (δ). NMR deconvolution was done on the software MestReNova.  
Gel Permeation Chromatography (GPC). The molecular weight and polydispersity were 
determined by gel permeation chromatography (Breeze 2 GPC, Waters), with Styragel HT 
column (Waters). Dimethylformamide (DMF) containing 20 mM LiBr was used as the eluent, 
with the elution rate of 1 mL min
-1
. Polystyrene standards were used for calibration. 
Fourier Transform Infrared Spectroscopy (FT-IR). Infrared spectra were obtained on NEXUS 
670 serial FTIR spectrophotometer.  
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2.4.2 Synthesis of mP-iA5 Conjugates 
 
Poly(HPMA-co-NHSMA) 3’: To an oven dried 20 mL Schlenk tube were added HPMA 1 (0.64 
g, 4.4 mmol), t-BuOH (2.2 mL), and 100 L CIDB solution in DMF (12.16 mg, 5.5 × 10-2 
mmol). Approximately 100 L AIBN solution in DMF (4.8 mg, 2.76 × 10-2 mmol) was 
transferred to the Schlenk tube. In another oven dried Schlenk tube, NHSMA 2 (0.8 g, 4.4 mmol) 
was dissolved in 4.0 mL anhydrous DMF. Both of the Schlenk tubes were sealed and subjected 
to five freeze-pump-thaw cycles. The reaction was carried out at 80 °C. The NHSMA solution 
was taken in a 5.0 mL airtight syringe and continuously added to the HPMA solution over 4 h 
using a syringe pump (PHD 2000, Harvard Apparatus). After the addition of NHSMA, the 
reaction was allowed to continue for additional 6 h. When the reaction completed, the Schlenk 
tube was rapidly cooled. The crude product was precipitated in diethyl ether/acetone (400 mL, 
1:1 v/v) and the copolymer was collected as pink solid. Copolymer 3' was further washed several 
times with diethyl ether/acetone and immediately dried under vacuum overnight (yield: 1.12 g, 
78%). 
The copolymer composition was determined by 
1
H NMR spectroscopy (28 mol% of NHSMA 
and 72 mol% of HPMA). 
1
H NMR (400 MHz, DMSO-d6) δ 7.85~7.73 (br, Ph-CSS-), 7.73~7.00 
(br, -CO-NH-), 4.78~4.41 (br, HO-CH(CH3)-CH2-), 3.90~3.47 (br, HO-CH(CH3)-CH2-), 3.20-
2.55 (br, HO-CH(CH3)-CH2-, succinimide), 2.40~1.47 (br, -CH2-C-), 1.46~0.42 (br, CH3-). 
Molecular weight and polydispersity were determined by DMF GPC (Mn = 49 kDa, PDI = 1.1). 
The degree of polymerization is approximately 300. Accordingly, the number of repeating unit 
NHSMA is 300 × 28% = 84, while the number of repeating unit HPMA is 300 × 72% = 216. 
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Figure 2.3 
1
H NMR spectrum and deconvolution result of poly(HPMA-co-NHSMA) 3’ in DMSO-
d6. Black line is original spectrum, blue lines are deconvoluted peaks, red lines are sum of 
deconvoluted peaks, grey lines are residues. 
 
Figure 2.4 GPC trace of poly(HPMA-co-NHSMA) 3’. 
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Poly(HPMA-co-NHSMA) 3: Poly(HPMA-co-NHSMA) 3’ (1.0 g, Mn = 49 kDa, 28 mol% 
NHSMA), AIBN (430 mg, 2.62 mmol) and anhydrous DMF (3 mL) were added to a 10 mL 
round bottom flask. The resulting solution was heated to 80 °C for 90 minutes. The copolymer 
was precipitated in a mixture of diethyl ether/acetone (400 mL, 1:1 v/v). The precipitate was 
collected as white powder and dried under vacuum overnight (yield: 0.88 g, 88%). The absence 
of the dithiobenzoate end group was confirmed by 
1
H NMR spectroscopy. 
1
H NMR (400 MHz, 
DMSO-d6) δ 7.73~7.00 (br, -CO-NH-), 4.78~4.41 (br, HO-CH(CH3)-CH2-), 3.90~3.47 (br, HO-
CH(CH3)-CH2-), 3.20-2.55 (br, HO-CH(CH3)-CH2-, succinimide), 2.40~1.47 (br, -CH2-C-), 
1.46~0.42 (br, CH3-). FT-IR (cm
-1
): 3687-3060 (O-H, N-H), 2974 (-CH3), 2935 (-CH2-), 1735 (-
N-C=O of NHS), 1665 (amide I of HPMA), 1531 (amide II of HPMA), 1203 (C-O). 
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Figure 2.5 
1
H NMR spectrum of poly(HPMA-co-NHSMA) 3 in DMSO-d6. 
 
Figure 2.6 IR spectrum of poly(HPMA-co-NHSMA) 3 (KBr). 
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Multivalent PHPMA-iA5 (mP-iA5) Conjugates 4 (mP- iA5-7% 4): Poly(HPMA-co-
NHSMA) 3, (100 mg, 28 mol% NHSMA, Mn = 49 kDa) and peptide NH2-LPFFD-CONH2 (80 
mg, 0.126 mmol) were dissolved in anhydrous DMSO (0.5 mL) in a 5 mL round bottom flask. 
The flask was sealed with a rubber stopper and purged with argon for 2 minutes. Then 
triethylamine (70 L, 0.504 mmol) was injected. The reaction was carried out at 65 °C for 24 h, 
followed by quenching with 1-amino-2-propanol. The polymer solution was precipitated in a 
mixture of diethyl ether/acetone (40 mL, 1:1 v/v). The precipitate was collected as white powder 
and dried under vacuum. The crude product was dissolved in distilled water and washed over an 
Amicon filter (Millipore, catalog NO. UFC 801024) for 8 times to remove unreacted peptide and 
other organic reagents. The amount of attached peptides was determined by 
1
H NMR 
spectroscopy (3%, 7%, and 12% conjugation). 
1
H NMR (400 MHz, CD3OD) δ 7.72~7.35 (br, -
CO-NH- in PHPMA), 7.35~6.90 (br, phenyl groups in iA5), 4.05~3.73 (br, HO-CH(CH3)-CH2-), 
3.27~2.78 (br, d, HO-CH(CH3)-CH2-), 2.45~1.56 (br, -CH2-C- in polymer backbone), 1.55~0.73 
(br, CH3-). FT-IR (cm
-1
): 3687-3060 (O-H, N-H), 2974 (-CH3), 2935 (-CH2-), 1665 (amide I), 
1564 (phenyl on penta-peptide), 1535 (amide II), 1205 (C-O). 
Table 2.1 Reaction conditions for peptide attachment onto poly(HPMA-co-NHSMA) 3. 
mP-iA5 
conjugates 4 
poly(HPMA-co-
NHSMA) 3 
iA5 triethylamine DMSO 
mP- iA5-3% 4 100 mg 
0.002 mmol 
34 mg 
0.054 mmol 
30 L 
0.216 mmol 
0.5 ml 
mP- iA5-7% 4 100 mg 
0.002 mmol 
80 mg 
0.126 mmol 
70 L 
0.504 mmol 
0.5 ml 
mP- iA5-12% 4 100 mg 
0.002 mmol 
137 mg 
0.216 mmol 
120 L 
0.864 mmol 
0.5 ml 
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Figure 2.7 
1
H NMR spectrum and deconvolution result of mP-iA5-3% 4 in CD3OD. Black line 
is original spectrum, blue lines are deconvoluted peaks, red lines are sum of deconvoluted peaks, 
grey lines are residues. 
Table 2.2 Deconvolution result of mP- iA5-3% 4. 
Peak Shift (ppm) Area 
b 7.29 1844 
b’ 7.20 2412 
d 3.17 17011 
d’ 2.97 14264 
 
Loading ratio =  
(1844 + 2412)/10
17011 + 14264
2 +
1844 + 2412
10
= 3% 
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Figure 2.8 IR spectrum of mP-iA5-3% 4 (KBr). 
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Figure 2.9 
1
H NMR spectrum and deconvolution result of mP-iA5-7% 4 in CD3OD. Black line 
is original spectrum, blue lines are deconvoluted peaks, red lines are sum of deconvoluted peaks, 
grey lines are residues. 
 
Table 2.3 Deconvolution result of mP- iA5-7% 4. 
Peak Shift (ppm) Area 
b 7.27 5653 
b’ 7.21 10642 
d 3.16 25804 
d’ 3.00 18607 
 
Loading ratio =  
(5653 + 10642)/10
25804 + 18607
2 +
5653 + 10642
10
= 7% 
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Figure 2.10 IR spectrum of mP-iA5-7% 4 (KBr). 
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Figure 2.11 
1
H NMR spectrum and deconvolution results of mP-iA5-12% 4 in CD3OD. Black 
line is original spectrum, blue lines are deconvoluted peaks, red lines are sum of deconvoluted 
peaks, grey lines are residues. 
Table 2.4 Deconvolution result of mP-iA5-12% 4. 
Peak  Shift (ppm) Area 
b 7.25 8232 
b’ 7.17 11153 
d 3.14 13725 
d’ 2.96 13152 
 
Loading ratio =  
(8232 + 11153)/10
13725 + 13152
2 +
8232 + 11153
10
= 12% 
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Figure 2.12 IR spectrum of mP-iA5-12% 4 (KBr). 
 
 
 
 
 
 
31 
 
 
Control Polymer 5: Poly(HPMA-co-NHSMA) 3 (100 mg, 28 mol % NHSMA, Mn = 49 kDa) 
and 1-amino-2-propanol (96 L, 1.3 mmol) were dissolved in anhydrous DMSO (0.5 mL) in a 5 
mL round bottom flask. The flask was sealed with a rubber stopper and purged with argon for 2 
minutes. The reaction was heated at 65 °C for 8 h. The polymer solution was precipitated in a 
mixture of diethyl ether/acetone (40 mL, 1:1 v/v). The precipitate was collected as white powder 
and dried under vacuum. The crude product was dissolved in distilled water and washed over an 
Amicon filter (Millipore, catalog NO. UFC 801024) for 8 times to remove unreacted peptide and 
other organic reagents. 
1
H NMR (400 MHz, CD3OD) δ 7.72~7.35 (br, -CO-NH- in PHPMA), 
4.05~3.73 (br, HO-CH(CH3)-CH2-), 3.27~2.78 (br, d, HO-CH(CH3)-CH2-), 2.45~1.56 (br, -CH2-
C- in polymer backbone), 1.55~0.73 (br, CH3-). FT-IR (cm
-1
): 3687-3060 (O-H, N-H), 2974 (-
CH3), 2935 (-CH2-), 1665 (amide I of HPMA), 1535 (amide II of HPMA), 1205 (C-O). 
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Figure 2.13 
1
H NMR spectrum of control polymer 5 in CD3OD. 
 
Figure 2.14 IR spectrum of control polymer 5 (KBr). 
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2.4.3 Binomial Distribution of iA5 Attached to mP-iA5 Conjugates 
If the conjugation of iA5 on polymer backbone follows binomial distribution, the 
probability (P) of finding x copies of iA5 on a polymer chain can be represented by the 
following equation: 
P (x = k) = C(n, k)𝑝𝑘(1 − 𝑝)𝑛−𝑘 
Where x is the number of iA5 per chain, n (n = 84) is the number of repeating unit 
NHSMA in the poly (HPMA-co-NHSMA). Lowercase p is the probability that an iA5 molecule 
will conjugate on a polymer chain, which can be represented by the average number of iA5 per 
chain divided by the number of repeating unit NHSMA. For mP-iA5-3% 4, p = 9 / 84 = 0.107; 
for mP-iA5-7% 4, p = 21 / 84 = 0.25; for mP-iA5-12% 4, p = 36 / 84 = 0.429. 
 
Figure 2.15 Binomial distribution of iA5 per chain.  
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Chapter 3: Modulatory Effect of Polymer-Peptide Conjugates on                   
A Aggregation 
3.1 Introduction 
Mechanistically, A fibrillar self-assembly is a supramolecular polymerization process 
which consists of two phases: a slow nucleation phase followed by a rapid elongation phase. 
During nucleation, the noncovalent interactions between monomers are weak and the initial 
oligomerization is energetically disfavored.
1
 In order to control the assembly process of A, we 
speculate the mP-iAβ5 conjugates should target species in the slow nucleation phase before the 
aggregation enters the fast elongation phase. The mP-iAβ5 conjugates were coincubated with 
freshly prepared Amonomer solution, and the aggregation kinetics was monitored by 
Thioflavin T (ThT) fluorescence assays. The aggregation-induced morphology changes were 
monitored by atomic force microscopy (AFM) and transmission electron microscopy (TEM) in 
dry phase, and dynamic light scattering (DLS) in solution phase.  
We demonstrate that mP-iAβ5 conjugates effectively modulate Aβ40 aggregation and 
redirect the formation of one-dimensional Aβ40 fibrils in microscale into uniform zero-
dimensional discrete nanostructures. Such uniform stabilized nanostructures of Aβ40 were rarely 
reported in the previous literatures, since the control of Aβ40 fibrillation to form structurally well-
defined assemblies remains largely unknown and challenging.
2-5
 To optimize the modulatory 
effect of conjugates on Aβ40 aggregation, we investigate the influence of tuning multivalency and 
specificity of the conjugates structures. The structure-activity relationship was explored from the 
following three aspects: tuning the loaing ratio of iAβ5, tuning the molecular weight of polymer, 
changing the attached Aβ40 recognition peptide sequences (Figure 3.1). 
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Figure 3.1 Optimization of modulatory effects by tuning the molecular architecture of polymer-
peptide conjugates from three aspects. 
3.2 mP-iA5 Conjugates Redirect A Aggregation into Discrete Nanostructures  
We first monitor the modulatory effect of mP-iAβ5 conjugates on A by ThT 
fluorescence assays. ThT assays of A aggregation typically display a sigmoidal curve 
comprising three phases: lag phase, growth phase, and equilibrium phase. The lag phase 
generally corresponds to lack of mature A fibrils. The rapid growth phase indicates increasing 
A fibrils concentration. Finally, the aggregation process reaches equilibrium phase when most 
of A peptides are converted to mature fibrils. In ThT assays the upturn in fluorescence follows 
a characteristic lag time that is extensively used to estimate the modulatory effects of inhibitors 
on Aβ aggregation.6-8 A longer lag time generally corresponds to a slower nucleation kinetics 
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and a better modulatory effect. Different color data points correspond to data from multiple runs 
under identical experimental conditions in the same plate. 
In the experimental time frame, mP-iA5 conjugates 4 suppressed A40 fibrillation at 0.5 
and 1.0 equiv. When A40 was incubated with 0.5 or 1.0 equiv of mP-iA5 conjugates 4, ThT 
assays exhibited prolonged lag phases without growing phase and equilibrium phase (Figure 3.2b, 
c, d, 3.3b, c, d), suggesting the lack of mature A40 fibrils. The conjugates with three different 
loading ratios show similar results. As control, A40 was incubated with 10.5 equiv and 21 equiv 
of iA5 (10.5 equiv and 21 equiv correspond to iA5 copies attached to 0.5 and 1.0 equiv of mP-
iA5-7% 4), and iA5 did not show significant modulatory effect (Figure 3.2e, 3.3e). A40 was 
also incubated with 0.5 and 1.0 equiv of control polymer 5. In both cases, although A40 
aggregation was delayed, typical sigmoidal curves were observed from ThT assays (Figure 3.2f, 
3.3f), indicating the formation of mature A40 fibrils. When A40 was incubated with the mixture 
of control polymer 5 and iA5, ThT data showed that the modulatory effects were similar as that 
of polymer 5 itself (Figure 3.2g, 3.3g). These results from ThT assays together demonstrate that 
the enhanced activity of mP-iA5 conjugates 4 mainly results from the multivalent effect. 
 
Figure 3.2 Inhibitory effect of 0.5 equiv of mP-iA5 conjugates 4 on A40 aggregation monitored 
by ThT fluorescence assays over 24 h. A40 control (15 M, 1.0 equiv) (a), A40 with 7.5 M of 
mP-iA5-3% 4 (0.5 equiv) (b), A40 with 7.5 M of mP-iA5-7% 4 (0.5 equiv) (c), A40 with 7.5 
38 
 
Figure 3.2 (cont.)M of mP-iA5-12% 4 (0.5 equiv) (d), A40 with 157.5 M of iA5 (10.5 equiv) 
(e), A40 with 7.5 M of control polymer 5 (0.5 equiv) (f), A40 with 157.5 M of iA5 (10.5 equiv) 
and 7.5 M of control polymer 5 (0.5 equiv) (g). ThT assays were performed in 10 mM PBS 
buffer (pH 7.4) at 37 °C with shaking (567 rpm). 
 
Figure 3.3 Inhibitory effect of 1.0 equiv of mP-iA5 conjugates 4 on A40 aggregation monitored 
by ThT fluorescence assays over 24 h. A40 control (15 M, 1.0 equiv) (a), A40 with 15 M of 
mP-iA5-3% 4 (1.0 equiv) (b), A40 with 15 M of mP-iA5-7% 4 (1.0 equiv) (c), A40 with 15 
M of mP-iA5-12% 4 (1.0 equiv) (d), A40 with 315 M of iA5 (21 equiv) (e), A40 with 15 M 
of control polymer 5 (1.0 equiv) (f), A40 with 315 M of iA5 (21 equiv) and 15 M of control 
polymer 5 (1.0 equiv) (g). ThT assays were performed in 10 mM PBS buffer (pH 7.4) at 37 °C 
with shaking (567 rpm).  
These ThT results were confirmed by AFM and TEM studies. Characterizations by AFM 
and TEM show that mP-iAβ5 conjugates 4 not only modulate Aβ40 aggregation but also redirect 
from forming long, unbranched, one-dimensional fibrillar microstructures to the formation of 
zero-dimensional discrete nanostructures. All the AFM and TEM samples were taken directly 
from ThT fluorescence assays after incubation of 24 h. When Aβ40 was incubated with 1.0 equiv 
of mP-iAβ5 conjugates 4 formed zero-dimensional discrete nanostructures at the end of the ThT 
experiments rather than the one dimensional fibrils which were otherwise formed by Aβ40 
control without any modulators (Figures 3.4, 3.5). When concentrations decreased to 0.5 equiv, 
mP-iAβ5-7% 4 and mP-iAβ5-12% 4 still stabilized Aβ40 into discrete nanostructures (Figures 
3.4c’, d’, 3.5c’, d’). However, mP-iAβ5-3% 4 did not fully stabilize Aβ40 into discrete 
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nanostructures at 0.5 equiv; instead, fibrils and nanostructures were both observed by AFM and 
TEM (Figures 3.4b′, 3.5b′). Controls based on both polymer 5 and iAβ5 do not have the ability to 
redirect Aβ aggregation to form discrete nanostructures. When A40 was incubated with control 
polymer 5 or iA5, truncated A40 fibrils were observed, and the amount of fibrils were much 
less than A40 control without any modulators (Figures 3.6, 3.7). The results from control groups 
indicate that control polymer 5 and iA5 do not fully suppress A40 fibrillization.   
 
Figure 3.4 AFM images of A40 after incubation for 24 h with or without mP-iA5 conjugates 4.  
A40 control (15 M, 1.0 equiv) (a), A40 with 15 M of mP-iA5-3% 4 (1.0 equiv) (b), with 7.5 
M of mP-iA5-3% 4 (0.5 equiv) (bʹ), A40 with 15 M of mP-iA5-7% 4 (1.0 equiv) (c), A40 
with 7.5 M of mP-iA5-7% 4 (0.5 equiv) (cʹ), A40 with 15 M of mP-iA5-12% 4 (1.0 equiv) 
(d), A40 with 7.5 M of mP-iA5-12% 4 (0.5 equiv) (dʹ). AFM images are 2 × 2 M and vertical 
scale bars are all 15 nm. 
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Figure 3.5 TEM images of A40 after incubation for 24 h with or without mP-iA5 conjugates 4.  
A40 control (15 M, 1.0 equiv) (a), A40 with 15 M of mP-iA5-3% 4 (1.0 equiv) (b), with 7.5 
M of mP-iA5-3% 4 (0.5 equiv) (bʹ), A40 with 15 M of mP-iA5-7% 4 (1.0 equiv) (c), A40 
with 7.5 M of mP-iA5-7% 4 (0.5 equiv) (cʹ), A40 with 15 M of mP-iA5-12% 4 (1.0 equiv) 
(d), A40 with 7.5 M of mP-iA5-12% 4 (0.5 equiv) (dʹ). 
 
Figure 3.6 AFM images of A40 after incubation for 24 h with or without iA5 or control polymer 
5.  A40 control (15 M, 1.0 equiv) (a), A40 with 315 M of iA5 (21 equiv) (b), with 157.5 M 
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Figure 3.6 (cont.) of iA5 (10.5 equiv) (bʹ), A40 with 15 M of control polymer 5 (1.0 equiv) (c), 
A40 with 7.5 M of control polymer 5 (0.5 equiv) (cʹ). AFM images are 2 × 2 M and vertical 
scale bars are all 15 nm. 
 
Figure 3.7 TEM images of A40 after incubation for 24 h with or without iA5 or control polymer 
5. A40 control (15 M, 1.0 equiv) (a), A40 with 315 M of iA5 (21 equiv) (b), with 157.5 M 
of iA5 (10.5 equiv) (bʹ), A40 with 15 M of control polymer 5 (1.0 equiv) (c), A40 with 7.5 M 
of control polymer 5 (0.5 equiv) (cʹ). 
3.3 Size Measurements on Discrete Nanostructures 
In order to further characterize the size and polydispersity of A nanostructures 
stabilized by mP-iA conjugates, we utilized cross sectional AFM image, statistical TEM, and 
DLS.  
Cross sectional AFM show that, when A was incubated for 24 h with 15 M of mP-
iA5-3%, dimensions of discrete nanostructures along cross-section are: 28.0 nm diameter/3.2 
nm height, 28.0 nm diameter/3.6 nm height, and 28.0 nm diameter/3.7 nm height (Figure 3.8a), 
30.0 nm diameter/3.5 nm height, 30.0 nm diameter/4.5 nm height, 35.0 nm diameter/4.0 nm 
height, and 30.0 nm diameter/4.1 nm height (Figure 3.8b). When A was incubated for 24 h 
with 15 M of mP-iA5-7%, dimensions of discrete nanostructures along cross-section are: 26.0 
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nm diameter/3.9 nm height, 26.0 nm diameter/4.3 nm height, and 30.0 nm diameter/4.7 nm 
height (Figure 3.8c), 30.0 nm diameter/4.2 nm height, 25.0 nm diameter/4.1 nm height, and 25.0 
nm diameter/3.4 nm height, 21.0 nm diameter/4.6 nm height, and 25.0 nm diameter/3.7 nm 
height (Figure 3.8d). When A was incubated for 24 h with 15 M of mP-iA5-12%, 
dimensions of discrete nanostructures along cross-section are: 23.0 nm diameter/3.6 nm height, 
23.0 nm diameter/3.7 nm height, and 27.0 nm diameter/4.3 nm height (Figure 3.8e), 28.0 nm 
diameter/4.1 nm height and 28.0 nm diameter/3.4 nm height (Figure 3.8f). To make a 
comparison between the size of stabilized nanostructures and A oligomers, A(15 M) was 
incubated for 1.5 h to form oligomers and the size was characterized by cross-sectional AFM. 
Dimensions of oligomers along cross-section are: 36.0 nm diameter/3.5 nm height, 36.0 nm 
diameter/3.2 nm height, and 36.0 nm diameter/3.3 nm height (Figure 3.8h). 
 
Figure 3.8 Cross-sectional AFM images of A after incubation for 24 h with 15 M of mP-
iA5-3% 4 (1.0 equiv) (a,b), with 15 M of mP-iA5-7% 4 (1.0 equiv) (c,d,g), with 15 M of mP- 
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Figure 3.8 (cont.) iA5-12% 4 (1.0 equiv) (e,f). Comparison between A-derived discrete 
nanostructures and A oligomers (h). AFM images are 2 × 2 M.  
Statistics of discrete nanostructures size distribution was done manually based on the 
zoomed out TEM images. Seven hundred nanostructures were counted in each sample, and the 
nanostructures were grouped according to different diameters by a range of 5 nm. Statistical 
results show that A-derived discrete nanostructures are approximately 5-35 nm. 
 
Figure 3.9 Size distribution of A-derived discrete nanostructures from TEM studies. Zoom out 
TEM images of A (15 M, 1.0 equiv) were recorded after 24 h incubation with 1.0 equiv of 
mP-iA5-3% 4 (a1), with 1.0 equiv of mP-iA5-7% 4 (a2), with 1.0 equiv of mP-iA5-12% 4 (a3). 
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Figure 3.9 (cont.) TEM statistical results of size distribution of discrete nanostructures formed 
from co-incubation of A (15 M, 1.0 equiv) with 1.0 equiv of mP-iA5-3% 4 (b1), with 1.0 
equiv of mP-iA5-7% 4 (b2), with 1.0 equiv of mP-iA5-12% 4 (b3).  
Dynamic light scattering (DLS) was used to determine the size distribution of A-
derived discrete nanostructures in solution. Samples of A (15 M, 1.0 equiv) with or without 
1.0 equiv of mP-iA5 conjugates 4 were incubated in 10 mM PBS buffer solution at 37 
o
C for 
24h in BioTek Hybrid H1 plate reader. The shaking and incubation conditions were the same as 
those in ThT assays, but ThT was not added to DLS samples. 
 
Figure 3.10 Size distribution of A-derived discrete nanostructures from DLS studies. The 
aggregates formed by incubation of A (15 M) alone (a), discrete nanostructures formed by 
co-incubation of A (15 M, 1.0 equiv) with 1.0 equiv of mP-iA5-3% 4 (b), with 1.0 equiv of 
mP-iA5-7% 4 (c), with 1.0 equiv of mP-iA5-12% 4 (d). 
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3.4 Hypothesis of Nanostructure Formation 
It is surprising that Aβ peptides self-assemble into discrete nanostructures in the presence 
of mP-iAβ5 conjugates 4. Although the composition of the discrete nanostructures has not been 
determined, we speculate that Aβ oligomers smaller than the critical-sized nucleus complex with 
conjugates 4 through multiple β-sheet interactions (Figure 3.11). These multivalent contacts 
prevent the Aβ nucleus from forming, and instead confine Aβ oligomers to a compact 
nanostructure, although we cannot exclude other possibilities such as interactions between Aβ 
monomers with conjugates 4 which initiate the formation of the discrete nanostructures. 
 
Figure 3.11 Hypothesis-based schematic representation of A40-dereived discrete nanostructure 
formation.  
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3.5 Investigating Peptide Loading Ratio Effect of Polymer-Peptide Conjugates on 
Modulation of A Aggregation 
ThT assays demonstrate that the multivalent design of mP-iAβ5 conjugates 4 leads to the 
enhanced activity against Aβ aggregation when compared to monovalent iAβ5. However, the 
conjugates with 3 different loading ratios show similar results at high concentration (1.0 equiv). 
In order to differentiate the modulatory effects of conjugates with different loading ratio, we 
decrease the concentration of conjugates to 0.1 equiv, at which concentration Aβ aggregation is 
not fully inhibited. By the comparison between the lag times in ThT assays, the optimized 
loading ratio is determined. 
In the presence of 2.1 equiv of iAβ5 per Aβ (2.1 equiv of iAβ5 approximately equal to the 
amount of iAβ5 copies attached to 0.1 equiv of mP-iAβ5-7% 4), the lag time did not significantly 
change when compared to that of Aβ40 control without any modulators (Figure 3.11e, a). In 
contrast, mP-iAβ5-3% conjugate 4 delayed Aβ aggregation by 83% at 0.1 equiv, increasing the 
lag time from 240 to 440 min. Moreover, mP-iAβ5-7% 4 delayed Aβ aggregation by 171% at 0.1 
equiv, increasing the lag time from 240 to 650 min, while mP-iAβ5-12% 4 delayed Aβ 
aggregation by 75% at 0.1 equiv, increasing the lag time from 240 to 420 min (Figure 3.11b, c, 
and d). These results indicate that mP-iAβ5 conjugates 4 (0.1 equiv) are much more active than 
monovalent iAβ5 (2.1 equiv). To investigate the effect of the PHPMA polymer backbone on Aβ 
aggregation, we incubated Aβ in the presence of 0.1 equiv of control polymer 5 with and without 
2.1 equiv of iAβ5. Our ThT data show that both polymers control only slightly delayed Aβ 
aggregation (Figure 3.11f, g). The lag time from the above ThT assays are plotted into the bar 
graph as shown in Figure 3.12. Accordingly, the ThT assays confirm that the enhanced activities 
of conjugates 4 mainly result from the multivalent effect. In addition, ThT results indicate that 
higher loading of conjugates 4 do not necessarily lead to slower nucleation kinetics and better 
modulatory effect. Instead, mP-iAβ5-7% 4 achieves the longest delay against Aβ aggregation, 
which suggests an optimal peptide loading. One possible explanation for this observation is that 
the peptides in mP-iAβ5-12% 4 start to self-associate, thereby competing with their 
intermolecular interactions to Aβ.9 The above results demonstrate that at substoichiometric 
concentrations, mP-iAβ5 conjugates 4 delay Aβ fibril formation in a loading dependent manner.  
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Figure 3.12 Modulatory effect of 0.1 equiv of mP-iA5 conjugates 4 on A aggregation 
monitored by ThT fluorescence assays over 24 h. A control (15 M, 1.0 equiv) (a), A with 
1.5 M of mP-iA5-3% 4 (0.1 equiv) (b), A with 1.5 M of mP-iA5-7% 4 (0.1 equiv) (c), A 
with 1.5 M of mP-iA5-12% 4 (0.1 equiv) (d), A with 31.5 M of iA5 (2.1 equiv) (e), A 
with 1.5 M of control polymer 5 (0.1 equiv) (f), A with 31.5 M of iA5 (2.1 equiv) and 1.5 
M of control polymer 5 (0.1 equiv) (g). ThT assays were performed in 10 mM PBS buffer (pH 
7.4) at 37 °C with shaking (567 rpm).  
 
Figure 3.13 Modulatory effect of mP-iA5 conjugates 4 on A aggregation monitored by 
Thioﬂavin T ﬂuorescence assays. Lag time of A aggregation in the absence or presence of mP-
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Figure 3.13 (cont.) iA5 conjugates 4. A prolonged lag time is an indicator of inhibition of A 
aggregation and slow nucleation kinetics. ThT assays were performed on 15 μM (1.0 equiv) Aβ 
peptide in 10 mmol PBS buffer (pH 7.4) at 37°C with 567 rpm shaking speed. (Results from T 
test, * p<1 x 10-3; ** p<1 x 10-4, *** p<1 x 10 -7) 
3.6 Investigating Molecular Weight Effect of Polymer-Peptide Conjugates on Modulation 
of A Aggregation 
In Chapter 3.5 we have demonstrated that 57 kDa mP-iA5 conjugates having on average 
of 7 mol% iA5 peptide per polymer chain achieved the optimized inhibitory effect compared to 
conjugates with 3 mol% and 12 mol% peptide loading ratio. To better understand the multivalent 
effect and investigate the influence of conjugates’ molecular weights on A aggregation, a 
series of mP-iA5 conjugates with the same 7% peptide loading and a range of molecular 
weights (15 kDa-224 kDa) were synthesized (Table 3.1). The modulatory effects of conjugates 
with different molecular weights were compared from two aspects: keeping the mol 
concentration of polymer chains the same or keeping the mol concentration of attached peptide 
the same. ThT fluorescence assays and AFM imaging studies were used to monitor the 
modulatory effect. 
Table 3.1 Molecular weights and average number of attached peptide on mP-iA5 conjugates. 
Molecular 
Weight 
15 kDa 22 kDa 46 kDa 90 kDa 166 kDa 224 kDa 
Average peptide 
per chain 
5.5 8.1 16.7 32.6 60.2 81.3 
 
When the mol concentration of polymer chains were kept the same, the conjugates with 
higher molecular weights have more copies of attached peptides. In the presence of 1.0 equiv of 
15 kDa mP-iA5 conjugates, A aggregation was delayed by 127%, lag time increasing from 
220 min to 500 min. As control, 15 kDa PHPMA polymer only slightly delayed A 
aggregation, and 5.5 equiv of iA5 free peptide did not significantly change the lag time (5.5 
equiv of iA5 approximately equal to the amount of iA5 copies attached to 1.0 equiv of 15 kDa 
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mP-iA5). Samples of AFM studies were taken directly from ThT assays after 24 h, and AFM 
confirmed the formation of A fibrils. 
 
Figure 3.14 Effects of 15 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (5.5 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 1.0 equiv of 22 kDa mP-iA5 conjugates, there was no typical 
sigmodal curve observed from ThT assay, but the fluorescent intensity gradually increased over 
time. AFM still shows the formation of A fibrils. As control, 22 kDa PHPMA polymer only 
slightly delayed A aggregation, and 8.1 equiv of iA5 free peptide did not significantly 
change the lag time (8.1 equiv of iA5 approximately equal to the amount of iA5 copies 
attached to 1.0 equiv of 22 kDa mP-iA5). AFM confirmed the formation of A fibrils in the 
control groups. 
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Figure 3.15. Effects of 22 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (8.1 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 1.0 equiv of 46 kDa mP-iA5 conjugates, there is no significant 
fluorescent signal observed from ThT assay, suggesting the lack of mature A fibrils. AFM 
confirmed the absence of fibrils. Instead, A was converted to the discrete nanostructures as 
shown in the original experimental group when A was coincubated with 57 kDa mP- iA5. As 
control, 46 kDa PHPMA polymer only slightly delayed A aggregation, and 16.7 equiv of iA5 
free peptide did not significantly change the lag time (16.7 equiv of iA5 approximately equal to 
the amount of iA5 copies attached to 1.0 equiv of 46 kDa mP-iA5). AFM confirmed the 
formation of A fibrils in the control groups. 
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Figure 3.16 Effects of 46 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (16.7 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 1.0 equiv of 90 kDa mP-iA5 conjugates, A aggregation was fully 
suppressed as indicated by ThT assay. AFM also confirmed that mP-iA5 conjugates redirect 
A aggregation into the formation of zero-dimensional discrete nanostructure. As control, 
when A was coincubated with 90 kDa PHPMA polymer, ThT assays did not show the typical 
sigmoidal curve, but still had slight fluorescent signal after 800 min. AFM confirmed the 
formation of A fibrils, although the fibrils are much thinner and shorter than previous control 
groups. In the presence of 32.5 equiv of iA5 free peptide (32.5 equiv of iA5 approximately 
equal to the amount of iA5 copies attached to 1.0 equiv of 90 kDa mP-iA5), the lag time was 
not significantly changed in ThT assays and AFM showed the presence of mature fibrils. 
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Figure 3.17 Effects of 90 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (32.5 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 1.0 equiv of 166 kDa mP-iA5 conjugates, A aggregation was fully 
suppressed as indicated by ThT assay. AFM also confirmed that mP-iA5 conjugates redirect 
A aggregation into the formation of zero-dimensional discrete nanostructure. As control, 
when A was coincubated with 166 kDa PHPMA polymer, ThT assays showed the slight 
fluorescent signal but AFM did not show mature fibrils formation. The above results suggested 
that 166 kDa PHPMA polymer also has the inhibitory effect on A aggregation, but not as 
efficient as mP-iA5 conjugates. Although PHPMA has no LPFFD, it is possible that PHPMA of 
high molecular weights interfere with A aggregation by multiple H-bonding through amide 
bond on the side chain of each repeating unit. In the presence of 60.1 equiv of iA5 free peptide 
(60.1 equiv of iA5 approximately equal to the amount of iA5 copies attached to 1.0 equiv of 
166 kDa mP-iA5), the lag time was not significantly changed in ThT assays. AFM showed no 
fibrils formation, but spherical nanostructures and worm-like short fibrils, the morphology are 
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not as uniform as the discrete nanostructures formed in the presence of mP-iA5 conjugates. The 
above results suggested that 60.1 equiv of iA5 free peptide is not as effective as 1 equiv of 46 
kDa mP-iA5 conjugates. 
 
Figure 3.18 Effects of 166 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (60.1 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 1.0 equiv of 224 kDa mP-iA5 conjugates, ThT and AFM studies 
showed similar results as the results when Awas coincubated with 166 kDa mP-iA5 
conjugates. The conjugates of 224 kDa were in excess amount and the excess conjugates 
incompletely covered the mica surface in a thin layer. The 166 kDa mP-iA5 conjugates 
incubated alone in the absence of A also left a thin layer of coverage on AFM. As control, 224 
kDa PHPMA polymer and 81.3 equiv LPFFD inhibited A aggregation similarly as the control 
groups of 166 kDa PHPMA polymer and 60.1 equiv LPFFD respectively. 
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Figure 3.19 Effects of 224 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (81.3 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm.  
Table 3.2 Summary of modulatory effects of mP-iAβ5 conjugates, control polymer, and iA with 
different molecular weights and same mol concentration of polymer chains on Aβ40 (15 μM). 
Molecular 
Weights 
Equiv 
of iA 
mP-iAβ5 Conjugates (1.0 equiv) Control Polymer (1.0 equiv) iA 
lag time of 
ThT (min) 
AFM 
lag time of 
ThT (min) 
AFM 
lag time of 
ThT (min) 
AFM 
22 kDa 8.1 
Fluorescence 
gradually increase 
fibrils 268 fibrils 200 fibrils 
46 kDa 16.7 
no lag time 
slight fluorescence 
nanostructures 318 fibrils 200 fibrils 
90 kDa 32.5 no fluorescence nanostructures 
slight 
fluorescence 
thin and short 
fibrils 
200 fibrils 
166 kDa 60.7 no fluorescence nanostrcutures   
slight 
fluorescence 
nanostrcutures 
peak at 
200 
no fibrils 
224 kDa 81.3 no fluorescence nanostrcutures 
slight 
fluorescence 
nanostrcutures 
peak at 
200 
no fibrils 

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To decouple the influence of molecular weight and the influence of the amount of 
attached LPFFD peptide on mP-iA5 conjugates, we compared the modulatory effects by 
keeping the mol concentration of attached peptide the same. We define 46 kDa conjugates as the 
standard and the mol concentration of other conjugates were calculated according to the different 
molecular weights. The mol concentration of the corresponding attached peptide is the same for 
all peptide control groups, which is 16.7 equiv. 
In the presence of 2.0 equiv of 22 kDa mP-iA5 conjugates, there was no typical 
sigmodal curve observed from ThT assay, but the fluorescent intensity gradually increased over 
time. AFM showed a mixture of short fibrils and spherical nanostructures. As control, 2 equiv of 
22 kDa PHPMA polymer and 16.7 equiv of iA5 free peptide did not significantly change the lag 
time AFM confirmed the formation of A fibrils in the control groups. The above results 
suggested that the modulatory effect of 1 equiv 46 kDa conjugates is better than that of 2 equiv 
of 22 kDa conjugates, although the amount of attached LPFFD peptides are the same. 
 
Figure 3.20 Effects of 22 kDa mP-iA5 conjugates (2.0 equiv), control polymer (2.0 equiv), and 
iA5 (16.7 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
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Figure 3.20 (cont.) performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with 
shaking (567 rpm). Samples of AFM studies were taken directly from the ThT assays. The scale 
bars are 500 nm.  
In the presence of 0.5 equiv of 90 kDa mP-iA5 conjugates, A aggregation was fully 
suppressed proved by ThT and AFM. As control, 0.5 equiv of 90 kDa PHPMA polymer and 16.7 
equiv of iA5 free peptide did not significantly change the lag time AFM confirmed the 
formation of A fibrils in the control groups. When A was co-incubated with 0.5 equiv 90 
kDa mP-iA5 conjugates, the ThT fluorescent intensity was lower than that when A was 
coincubated with 1.0 equiv of 46 kDa, which suggest that the modulatory effect of 0.5 equiv 90 
kDa conjugates is better than that of 1.0 equiv 46 kDa conjugates, although the amount of 
attached LPFFD peptides are the same.  
 
Figure 3.21 Effects of 90 kDa mP-iA5 conjugates (0.5 equiv), control polymer (0.5 equiv), and 
iA5 (16.7 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
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In the presence of 0.27 equiv of 166 kDa mP-iA5 conjugates, the fluorescent intensity of 
ThT assays gradually increased followed by a rapid increase by the end of experimental time 
frame. AFM studies showed mainly spherical nanostructures whose dimensions are bigger than 
that formed from the co-incubation of Aand 0.5 equiv 90 kDa conjugates. A small amount of 
short fibrils are also observed by AFM.  As control, 0.27 equiv of 166 kDa PHPMA polymer and 
16.7 equiv of iA5 free peptide did not significantly change the lag time AFM confirmed the 
formation of A fibrils in the control groups. The above results suggest that the modulatory 
effect of 0.5 equiv 90 kDa conjugates is better than that of 0.27 equiv 166 kDa conjugates, 
although the amount of attached LPFFD peptides are the same.  
 
Figure 3.22 Effects of 166 kDa mP-iA5 conjugates (0.27 equiv), control polymer (0.27 equiv), 
and iA5 (16.7 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  
We define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays 
were performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm. 
In the presence of 0.2 equiv of 224 kDa mP-iA5 conjugates, the ThT assays showed 
typical sigmoidal curve. A aggregation was delayed by 145%, lag time increasing from 220 
min to 550 min. AFM studies confirmed the fibrils formation, although much shorter and thinner 
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than the fibrils formed from A control. As control, 0.2 equiv of 224 kDa PHPMA polymer 
and 16.7 equiv of iA5 free peptide did not significantly change the lag time AFM confirmed the 
formation of A fibrils in the control groups. The above results suggest that the modulatory 
effect of 0.2 equiv 224 kDa conjugates is weaker than that of 0.27 equiv 166 kDa conjugates, 
although the amount of attached LPFFD peptides are the same. 
 
Figure 3.23 Effects of 224 kDa mP-iA5 conjugates (0.2 equiv), control polymer (0.2 equiv), and 
iA5 (16.7 equiv) on A aggregation monitored by ThT assays (top) and AFM (bottom).  We 
define equiv as the molar ratio of mP-iA5 conjugates or iA5 peptide to A. ThT assays were 
performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). 
Samples of AFM studies were taken directly from the ThT assays. The scale bars are 500 nm.  
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Table 3.3 Summary of modulatory effects of mP-iAβ5 conjugates, control polymer, and iA with 
different molecular weights and same amount of attached peptide on Aβ40 (15 μM).  
Molecular 
Weights 
Equiv of 
Polymer 
mP-iAβ5 Conjugates Control Polymer iA(16.7 equiv) 
lag time of 
ThT (min) 
AFM 
lag time of 
ThT (min) 
AFM 
lag time of 
ThT (min) 
AFM 
22 kDa 2.0 
no lag time 
slight fluorescence 
nanostrcutures  
short fibrils 
200 fibrils 
200 fibrils 
46 kDa 1.0 
no lag time 
slight fluorescence 
nanostructures 318 fibrils 
90 kDa 0.5 no fluorescence nanostructures 170 fibrils 
166 kDa 0.27 1400 
nanostrcutures  
short fibrils 
470 fibrils 
224 kDa 0.2 510 thin fibrils 350 fibrils 
 
 
Figure 3.24 Hypothesis of Amodulation by polymer-peptide conjugates of different molecular 
weights.  
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3.7 Investigating Peptide Sequence Effect of Polymer-Peptide Conjugates on Modulation of 
A Aggregation 
Apart from the multivalent design of mP-iA5 conjugates, the other design feature is the 
specificity of the attached peptide. To investigate the influence of peptide specificity on the 
modulatory effect, we designed and synthesized conjugates with different attached peptide 
sequences and the same peptide loading ratio. Previous studies have demonstrated that the 
optimized peptide loading ratio is 7%, and the initial molecular weight that fully inhibits A 
aggregation is 57 kDa, so 7% loading ratio and 57 kDa molecular weight were kept the same in 
the peptide sequences studies. ThT fluorescence assays and AFM imaging studies were used to 
monitor the modulatory effect. 
 
Figure 3.25 Different peptide sequences attached on polymer-peptide conjugates. 
In the initial studies, the sequence of LPFFD is derived from LVFFA
10,11
 and it has been 
demonstrated that the attached LPFFD efficiently bind to LVFFA sequence on A and prevent 
-sheet formation. We speculate that LVFFA pentapeptide has a high binding affinity to the 
same sequence in A. In addition, peptides targeting the central hydrophobic region of Aβ 
became lead sequences for optimization of Aβ amyloid inhibitors.12-14 Thus we choose LVFFA 
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as the attached peptide on conjugates and study whether mP-LVFFA conjugates bind to A and 
prevent A aggregation. 
 In the presence of 1.0 equiv and 0.5 equiv of mP-LVFFA conjugates, the fluorescent 
signal of ThT assays reached a high intensity at the beginning and kept the same level as the 
incubation continuing.  AFM studies showed fibrils formation, but the fibrils are significantly 
shorter and straighter compared to A control. In the presence of 0.1 equiv of mP-LVFFA 
conjugates, ThT assays showed the sigmoidal curves and AFM confirmed the fibrils formation.  
 
Figure 3.26 Effects of 7% mP-LVFFA-COOH conjugates (1.0 equiv, 0.5 equiv, and 0.1 equiv) on 
A aggregation monitored by ThT assays (top) and AFM (bottom).  We define equiv as the 
molar ratio of mP-LVFFA-COOH conjugate to A. ThT assays were performed on 15 M A 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). Samples of AFM studies were 
taken directly from the ThT assays. The scale bars are 500 nm. 
 To explore the reason why A formed short straight fibrils in the presence of mP-
LVFFA conjugates, we studied the effect of LVFFA free peptide on A aggregation. LVFFA 
peptide was incubated with or without A21 equiv of LVFFA approximately equal to the 
amount of peptide copies attached to 1.0 equiv of 57.0 kDa mP-LVFFA). No matter 
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Apresents or not, both of the control groups showed the typical sigmoidal curves and the lag 
time was the same as pure A control by ThT assays (Figure 3.27, 3.28). AFM studies 
confirmed that LVFFA free peptide aggregated into long unbranched fibrils, which are the same 
as the fibrils formed from Aitself (Figure 3.27, 3.28). Previous studies have shown that 
LVFFA central sequence plays an important role in A aggregation through hydrophobic 
interaction and -sheet formation. It is interesting that the aggregation kinetics and morphology 
of Aand pentapeptide LVFFA are the same, which indicated that LVFFA self-assembled into 
fibrils through the same hydrophobic interaction and -sheet formation.  Thus LVFFA is not the 
appropriate sequence for the design of conjugates. 
 
Figure 3.27 Effects of LVFFA-COOH (21 equiv, 10.5 equiv, and 2 equiv) on A aggregation 
monitored by ThT assays (top) and AFM (bottom).  We define equiv as the molar ratio of 
LVFFA-COOH to A. ThT assays were performed on 15 M A peptide in PBS buffer (pH 
7.4) at 37 C with shaking (567 rpm). Samples of AFM studies were taken directly from the ThT 
assays. The scale bars are 500 nm.   
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Figure 3.28 Aggregation of LVFFA-COOH (21 equiv, 10.5 equiv) in the absence of A 
monitored by ThT assays (top) and AFM (bottom)over 24 h. ThT assays were performed in 10 
mM PBS buffer (pH 7.4) at 37 °C with shaking (567 rpm). Samples of AFM studies were taken 
directly from the ThT assays. The scale bars are 500 nm.  
To attenuate the hydrophobic interaction and self-association of LVFFA, we incorporated 
charged residue in the sequences. We chose KLVFFA
12,13
 and KLVFFAE as the attached peptide 
and synthesized mP-KLVFFA and mP-KLVFFAE conjugates. The mP-KLVFFA conjugates 
formed an aqueous gel at 5 mg/mL and did not fully dissolved upon dilution, so mP-KLVFFA 
conjugates were not carried into A assays. The solutions of mP-KLVFFAE conjugates are 
viscous and need caution in preparation. The modulatory effects of mP-KLVFFAE conjugates on 
A aggregation were studied by ThT assays and AFM.  
When Ais co-incubated with mP-KLVFFAE conjugates, ThT assays had similar 
fluorescence response as when Ais co-incubated with mP-LVFFA conjugates. AFM studies 
showed that 1.0 equiv and 0.5 equiv of mP-KLVFFAE conjugates fully suppressed 
Aaggregation and Apeptides were stabilized into spherical nanostructures. In the presence 
of 0.1 equiv of mP-KLVFFAE conjugates, the lag time of ThT assays were delayed by 336%, 
increasing from 220 min to 960 min. AFM showed a mixture of short fibrils and spherical 
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nanostructures. ThT assays and AFM studies both suggested that the inhibitory effect of mP-
KLVFFAE conjugates is better than that of mP-iA5 conjugates. However, the high viscosity 
issue of mP-KLVFFAE solution may limit the future application. 
 
Figure 3.29 Effects of 7% mP-KLVFFAE-CONH2 (1 equiv, 0.5 equiv, and 0.1 equiv) on A 
aggregation monitored by ThT assays (top) and AFM (bottom).  We define equiv as the molar 
ratio of mP-KLVFFAE-CONH2 conjugates to A. ThT assays were performed on 15 M A 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). Samples of AFM studies were 
taken directly from the ThT assays. The scale bars are 500 nm.   
Previous literatures have reported that LVFFA central hydrophobic sequence forms a 
hairpin structure with AIIGL sequence close to C-terminal.
15
 Taking advantages of the 
interaction between LVFFA and AIIGL, we designed and synthesized conjugates with AIIGL as 
the attached peptide sequence. The modulatory effects of mP-AIIGL conjugates on A 
aggregation were studied by ThT assays and AFM. 
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Figure 3.30 Structural constraints in Aβ fibrils. (Reproduced with permission from Reference 15. 
Copyright © 2010 Nature Publishing Group) 
When A is co-incubated with mP-AIIGL conjugates of different equiv, the lag times 
of ThT assays were not significantly changed compared to A control, which indicated that 
mP-AIIGL conjugates had no obvious modulatory effect on A aggregation. AFM studies 
confirmed the fibrils formation, but the fibrils were not as long as A control group. In the 
presence of 1.0 equiv of mP-AIIGL conjugates, A aggregate into a mixture of fibrils and 
spherical nanostructures. We speculate that mP-AIIGL conjugates slightly changed the 
aggregation morphology of Aand have insignificant effect on the aggregation kinetics, which 
may due to the weak interaction between LVFFA and AIIGL. 
 
Figure 3.31 
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Figure 3.31 (cont.) Effects of 7% mP-AIIGL-COOH (1 equiv, 0.5 equiv, and 0.1 equiv) on A 
aggregation monitored by ThT assays (top) and AFM (bottom).  We define equiv as the molar 
ratio of mP-AIIGL-COOH conjugates to A. ThT assays were performed on 15 M A 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm). Samples of AFM studies were 
taken directly from the ThT assays. The scale bars are 500 nm.   
 
Figure 3.32 Effects of AIIGL-COOH (21 equiv, 10.5 equiv, and 2 equiv) on A aggregation 
monitored by ThT assays (top) and AFM (bottom).  We define equiv as the molar ratio of AIIGL-
COOH to A. ThT assays were performed on 15 M A peptide in PBS buffer (pH 7.4) at 37 
C with shaking (567 rpm). Samples of AFM studies were taken directly from the ThT assays. 
The scale bars are 500 nm.   
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Table 3.4 Summary of modulatory effects of polymer-peptide conjugates with different peptide 
sequences on Aβ40 (15 μM).  
Peptide Sequences  
on Conjugates (7%) 
ThT AFM Comments 
LPFFD-CONH2 Lag time of 650 min at 0.1 equiv. 
No fluorescence response at 0.5 
and 1.0 equiv. 
Nanostructures at 0.5 and 
1.0 equiv. 
The best sequence. 
LVFFA-CONH2 N/A N/A The conjugates are 
insoluable. 
LVFFA-COOH Flat lines with fluorescence 
response at 0.5 and 1.0 equiv. 
Short and rigid fibrils. LVFFA pentapeptide itself 
aggregates into fibrils. 
KLVFFA-CONH2 N/A N/A The conjugtes form gel in 
buffer solutions. 
KLVFFAE-CONH2 Lag time of 910 min at 0.1 equiv. 
Flat lines with fluorescence 
response at 0.5 and 1.0 equiv. 
Short fibrils at 0.1 equiv. 
Nanostructures at 0.5 and 
1.0 equiv. 
Viscous solutions. 
AIIGL-COOH Lag time of 220 min at 0.1, 0.5, 
and 1.0 equiv, the same as A40 
control 
Fibrils The interaction between 
LVFFA and AIIGL is weak. AII(Met)GL-COOH 
 
3.8 Experimental Details 
3.8.1 Materials and Methods 
Materials. N-hydroxysuccinimide methacrylate (NHSMA, 98%), 2-cyano-2-propyl 
benzodithioate (CIDB, >97%), Thioflavin T (ThT, dye content, ~75%), dimethyl sulfoxide 
(DMSO, anhydrous, >99.9%), N, N’-dimethylformamide (DMF, anhydrous, 99.8%), and tert-
butanol (anhydrous, 99.5%) were purchased from Sigma-Aldrich and used as received. 2,2′-
azobis(2-methylpropionitrile) perphenazine (AIBN, 98%) was purchased from Sigma-Aldrich 
and recrystallized before use. 1-amino-2-propanol (94%) was purchased from Acros. N-(2-
hydroxypropyl) methacrylamide (HPMA, 98%) was purchased from Polyscience. Amyloid  
protein (A40), LVFFA-COOH, cbz-KLVFFAE-CONH2, and AIIGL-COOH were purchased 
from GL Biochem Ltd. (Shanghai, China). Molecular biology grade water (ultrapure water) for 
ThT Assays was purchased from Corning. PBS buffer (100 mM) was purchased from Lonza (Cat 
No. 17-517Q, Lot No. 0000447701).  All other solvents (HPLC or spectroscopic grade) were 
purchased from Sigma-Aldrich or Fisher, and used as received. 
Nuclear Magnetic Resonance (NMR). 
1
H NMR spectra were obtained on a Varian Unity 400 
spectrometer in the School of Chemical Sciences NMR laboratory at the University of Illinois at 
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Urbana-Champaign. Spectra were referenced to residual solvent peaks. Chemical shifts are 
expressed in parts per million (δ). NMR deconvolution was done on the software MestReNova.  
Gel Permeation Chromatography (GPC). The molecular weight and polydispersity were 
determined by gel permeation chromatography (Breeze 2 GPC, Waters), with Styragel HT 
column (Waters). Dimethylformamide (DMF) containing 20 mM LiBr was used as the eluent, 
with the elution rate of 1 mL min
-1
. Polystyrene standards were used for calibration. 
Atomic Force Microscopy (AFM). Samples for AFM studies were taken directly from the ThT 
assays, and 10 L of each sample solution was loaded on freshly cleaved mica surface (Electron 
Microscopy Sciences, catalog NO. 71856-01). Samples were incubated for 5 minutes and rinsed 
with 5 drops of molecular biology grade water. The mica surface was blow-dried under nitrogen. 
AFM images were obtained on a MultiMode V (Bruker, Santa Barbara, USA) microscope in 
tapping mode. Ultrasharp silicon cantilevers (SCANASYST-ATR, Bruker) were used. All of the 
images were collected at a scan rate of 1 Hz and scan lines of 512. 
Transmission Electron Microscopy (TEM). Samples for TEM studies were taken directly from 
the ThT assays, and 5 L of each sample solution was loaded on a formvar carbon-coated copper 
grid (Ted Pella, catalog NO. 01822-F) for 1 minute. Then the grids were rinsed with molecular 
biology grade water followed by negatively staining using 2% uranyl acetate for 1 minute. The 
grids were allowed to dry overnight. TEM images were acquired using a Philips CM-200 
transmission electron microscope at an accelerating voltage of 120 kV. 
Dynamic Light Scattering (DLS). Samples for DLS studies were prepared at the same condition 
as in ThT assays without adding ThT dye molecules. The DLS studies were carried out using a 
particle sizer NICOMP 380 ZLS.  
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Quality certification of A40, HPLC, MS 
                  
Figure 3.33 Quality certification and HPLC trace of A40. 
 
Figure 3.34 ESI-MS spectrum of A40. 
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Quality certification of LPFFD-CONH2, HPLC, MS 
       
Figure 3.35 Quality certification and HPLC trace of LPFFD-CONH2. 
 
Figure 3.36 ESI-MS spectrum of LPFFD-CONH2. 
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Quality certification of LVFFA-COOH, HPLC, MS 
 
Figure 3.37 HPLC trace of LVFFA-COOH. 
 
Figure 3.38 ESI-MS spectrum of LVFFA-COOH. 
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Quality certification of KLVFFA-CONH2, HPLC, MS 
  
Figure 3.39 HPLC trace of KLVFFA-CONH2. 
 
Figure 3.40 ESI-MS spectrum of KLVFFA-CONH2. 
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Quality certification of KLVFFAE-CONH2, HPLC, MS 
 
Figure 3.41 HPLC trace of KLVFFAE-CONH2. 
  
Figure 3.42 ESI-MS spectrum of KLVFFAE-CONH2. 
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Quality certification of AIIGL-COOH, HPLC, MS 
 
Figure 3.43 HPLC trace of AIIGL-COOH. 
 
Figure 3.44 ESI-MS spectrum of AIIGL-COOH. 
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3.8.2 Synthesis of mP-iA5 Conjugates with Different Molecular Weights 
The mP-iA5 conjugates with different molecular weights were synthesized from 
Poly(HPMA-co-NHSMA) 3 following the synthetic procedure described in Chapter 2. The GPC 
traces are shown in Figure 3.45. 
 
Figure 3.45  GPC trace of mP-iA5 conjugates with different molecular weights. 
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3.8.3 Synthesis of 7% mP-LVFFA-COOH Conjugates 
 
Multivalent PHPMA-LVFFA-COOH Conjugates 6 (7% mP-LVFFA-COOH): Poly(HPMA-
co-NHSMA) 3, (70 mg, 28 mol% NHSMA, Mn = 49 kDa) and peptide NH2-LVFFA-COOH (60 
mg, 0.23 mmol) were dissolved in anhydrous DMSO (0.5 mL) in a 5 mL round bottom flask. 
The flask was sealed with a rubber stopper and purged with argon for 2 minutes. Then 
triethylamine (128 L, 0.92 mmol) was injected. The reaction was carried out at 65 °C for 24 h, 
followed by quenching with 1-amino-2-propanol. The polymer solution was precipitated in a 
mixture of diethyl ether/acetone (40 mL, 1:1 v/v). The precipitate was collected as white powder 
and dried under vacuum. The crude product was dissolved in distilled water and washed over an 
Amicon filter (Millipore, catalog NO. UFC 801024) for 8 times to remove unreacted peptide and 
other organic reagents. The amount of attached peptides was determined by 
1
H NMR 
spectroscopy (7% conjugation). 
1
H NMR (400 MHz, CD3OD) δ 7.35~7.05 (br, phenyl groups in 
LVFFA), 4.05~3.60 (br, HO-CH(CH3)-CH2-), 3.26~2.80 (br, d, HO-CH(CH3)-CH2-), 2.45~1.56 
(br, -CH2-C- in polymer backbone), 1.55~0.73 (br, CH3-).  
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3.8.4 Synthesis of 7% mP-cbz-KLVFFAE-CONH2 Conjugates 
 
Multivalent PHPMA-cbz-KLVFFAE-CONH2 Conjugates 7 (7% mP-cbz-KLVFFAE-
CONH2): Poly(HPMA-co-NHSMA) 3, (60 mg, 28 mol% NHSMA, Mn = 49 kDa) and peptide 
cbz-KLVFFAE-CONH2 (84 mg, 0.086 mmol) were dissolved in anhydrous DMSO (0.5 mL) in a 
5 mL round bottom flask. The flask was sealed with a rubber stopper and purged with argon for 
2 minutes. Then triethylamine (48 L, 0.504 mmol) was injected. The reaction was carried out at 
65 °C for 24 h, followed by quenching with 1-amino-2-propanol. The polymer solution was 
precipitated in a mixture of diethyl ether/acetone (40 mL, 1:1 v/v). The precipitate was collected 
as white powder and dried under vacuum. The crude product was dissolved in distilled water and 
washed over an Amicon filter (Millipore, catalog NO. UFC 801024) for 8 times to remove 
unreacted peptide and other organic reagents. The amount of attached peptide was determined 
after the removal of cbz protecting group in the next step. 
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Multivalent PHPMA-KLVFFAE-CONH2 Conjugates 8 (7% mP-KLVFFAE-CONH2): 7% 
mP-cbz-KLVFFAE-CONH2 7 (50 mg) was dissolved in HBr/HOAC (3 mL) in a 20 mL round 
bottom flask and stirred for 0.5 h. The amount of attached peptides was determined by 
1
H NMR 
spectroscopy (7% conjugation). 
1
H NMR (400 MHz, CD3OD) δ 7.37~6.95 (br, phenyl groups in 
KLVFFAE-CONH2), 3.96~3.75 (br, HO-CH(CH3)-CH2-), 3.27~2.78 (br, d, HO-CH(CH3)-CH2-), 
2.45~1.56 (br, -CH2-C- in polymer backbone), 1.55~0.73 (br, CH3-). 
3.8.5 Synthesis of 7% mP-AIIGL-COOH Conjugates 
 
Multivalent PHPMA-AIIGL-COO
-
 
+
NH3-R Conjugates 9 (7% mP-AIIGL-COO
-
): 
Poly(HPMA-co-NHSMA) 3, (80 mg, 28 mol% NHSMA, Mn = 49 kDa) and peptide NH2-
AIIGL-COOH (55 mg, 0.114 mmol) were dissolved in anhydrous DMSO (0.5 mL) in a 5 mL 
round bottom flask. The flask was sealed with a rubber stopper and purged with argon for 2 
minutes. Then triethylamine (63 L, 0.456 mmol) was injected. The reaction was carried out at 
65 °C for 24 h, followed by quenching with 1-amino-2-propanol. The polymer solution was 
precipitated in a mixture of diethyl ether/acetone (40 mL, 1:1 v/v). The precipitate was collected 
as white powder and dried under vacuum. The crude product was dissolved in distilled water and 
washed over an Amicon filter (Millipore, catalog NO. UFC 801024) for 8 times to remove 
unreacted peptide and other organic reagents. The amount of attached peptide was determined 
after the protonation in the next step. 
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Multivalent PHPMA-AIIGL-COOH Conjugates 10 (7% mP-AIIGL-COOH): 7% PHPMA-
AIIGL-COO
-
 
+
NH3-R 9 (37mg) was dissolved in water (4 mL) in a 20 mL vial and HCl (1M) 
was added to tune the pH to 4. The solution was purified over an Amicon filter (Millipore, 
catalog NO. UFC 801024) and dried by lyophilizer. The amount of attached peptides was 
determined by 
1
H NMR spectroscopy (7% conjugation). 
1
H NMR (400 MHz, DMSO-d6) δ 
12.78~11.81 (br, -COOH- in AIIGL) 7.72~7.35 (br, -CO-NH- in PHPMA), 4.78~4.47 (br, HO-
CH(CH3)-CH2-), 3.85~3.50 (br, d, HO-CH(CH3)-CH2-), 3.05~2.67 (br, d, HO-CH(CH3)-CH2-), 
2.23~1.42 (br, -CH2-C- in polymer backbone), 1.42~0.55 (br, CH3-). 
3.8.6 Thioflavin T Fluorescence Assays  
ThT fluorescence assays were conducted in 96-well black plate (Thermo Scientific 
NUNC, catalog NO. 265301) at 37 
o
C with continuous shaking (567 rpm) in a BioTek Hybrid 
H1 plate reader. ThT fluorescence was recorded with 10 minutes reading intervals and 5 s 
shaking before first read (442 nm excitation, 482 nm emission). All samples were run in 
quadruple or more. At least three independent experiments were carried out for each ThT assay. 
Each well contained 10 mM PBS buffer solution (pH 7.4) and 20 µM ThT in a total volume of 
200 L. Aβ40 (15 µM, 1.0 equiv), iA5, control polymer 5, and mP-iA5 conjugates 4 were 
added as needed. The concentrations of added samples were calculated based on A40 (15 µM, 
1.0 equiv). 
Preparation of Buffered ThT Solution. The ThT solution in 20 mM PBS was freshly prepared 
before use according to literature.
1
 Thioflavin T (4 mg) was dissolved in 20 mL of ultrapure 
water and filtered through a 0.22 micron filter. The concentration of the above solution was 
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determined by UV-Vis at 412 nm ( = 36000 M-1 cm-1). Based on the determined concentration 
of the ThT solution, ultrapure water and 100 mM PBS were further added to dilute the ThT 
solution to 40 M in 20 mM PBS, pH 7.4.  
Preparation of A40 Solution. The A40 solution was freshly prepared as following. A40 was 
dissolved in 100 mM NaOH (aq) to the concentration of 1.5 mM and sonicated for 30 seconds. 
The resulting solution was diluted to 300 M by adding ultrapure water. The solution was 
filtered through 100 kDa centricon filters (Pall Life Sciences, catalog NO. OD100C34) at 8000 
rpm for 8 minutes to remove any pre-aggregates. The freshly prepared solution was further 
diluted to 150 M by ultrapure water and used for assays.  
Sample Preparation. Conjugates 4 and control polymer 5 were dissolved in ultrapure water to 
0.15 mM and filtered by 0.22 micron syringe filter. Pentapeptide LPFFD was dissolved to 10 
times concentrated as needed concentration in ThT assays, and filtered by 0.22 micron syringe 
filter. The filtered solutions were further diluted to different concentrations. 
Preparation of Solutions for 96-well Plate. The buffered ThT solution, sample solutions and 
ultrapure water were mixed in a certain ratio and added to each well so that each well contained 
20 M ThT, 10 mM PBS, and different concentration of modulators (mP-iA5 conjugates 4, 
control polymer 5, and LPFFD). Then A40 solution (150 M, 20 L) was added to each well so 
that the final concentration of A40 was 15 M. The detailed preparation of 96-well plate is 
shown as following: 
For A40 with modulators: the buffered ThT solution (40 M, 100 L), modulators of 
different concentrations (20 L), and ultrapure water (60 L) were added and mixed. Then A40 
solution (150 M, 20 L) was added. For A40 without modulators: the buffered ThT solution 
(40 M, 100 L), and ultrapure water (80 L) were added and mixed. Then A40 solution (150 
M, 20 L) was added. For modulators without A40: the buffered ThT solution (40 M, 100 
L), modulators of different concentrations (20 L), and ultrapure water (80 L) were added and 
mixed. For ThT control without A40 and modulators: the buffered ThT solution (40 M, 100 
L), and ultrapure water (100 L) were added and mixed.  
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Chapter 4: Dissociation of Preformed A Fibrils by mP-iA5 Conjugates 
4.1 Introduction 
As we have discussed in Chapter 3, to provide mechanistic understanding and foundation 
to investigate potential treatments for amyloid diseases, extensive research have be done to 
inhibit amyloid aggregation and prevent the formation of neurotoxic species by designing 
modulators that kinetically control amyloid fibrillation.
1
 However, none of the previous 
modulators have been developed as therapeutic agents for the amyloid disease. The alternative 
strategy to treat amyloid diseases is to reduce the amount of the existing amyloid plaques by 
dissociating amyloid fibrils.
2,3
 However, this strategy remains a challenge as the amyloid fibrils 
are the stable final products of the aggregation pathway,
4
 and only a very few molecules have 
been reported to dissociate amyloid fibrils.
5-7
 In this Chapter, we report a new class of polymer-
based amyloid fibril breakers that dissociate the preformed A fibrils, and the dissociation 
kinetics are controlled by the molecular weights of polymers. Atomic force microscopy (AFM) 
and dynamic light scattering (DLS) studies show that mP-iA5 conjugates effectively 
disassemble microscale amyloid fibrils into nanostructures under 100nm. 
In Chapter 2 and 3, we introduce the design of multivalent polymer-peptide conjugates 
(mP-iA5) that coincubated with A monomer solution and inhibited A fibrillation by 
taking advantage of the nucleation-dependent kinetics of A aggregation. Through specific 
peptide interaction and multivalent effect, the mP-iA5 conjugates stabilized transient 
intermediates of A oligomers into discrete nanostructures. In Chapter 2, we have 
demonstrated that mP-iA5 conjugates having on average of 7 mol% iA5 peptide per polymer 
chain achieved the optimized inhibitory effect. In this Chapter, a series of mP-iA5 conjugates 
with the same 7% peptide loading and a range of molecular weights (15 kDa-220 kDa) were 
synthesized to investigate the dissociation effect on A fibrils (See Chapter 3.8.2 for synthetic 
details).  
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4.2 A Fibrils Dissociated by mP-iA5 Conjugates of Different Mn with Same mol 
Concentration of Polymer Chains  
To evaluate the ability of mP-iA5 to disassemble preformed A fibrils, we conducted 
experiments in which mP-iA5 conjugates were incubated with preformed fibrils. A40 (15 uM) 
were preincubated at 37 C for 24 h, which is sufficiently long enough for A to grow into mature 
fibrils as evidenced by AFM images and ThT fluorescence. Upon 24 h incubation, A fibrils 
solution was then coincubated with mP-iA5 with different molecular weights, and the mixture 
were co-incubated at 37 C for 3 days. The dissociation effects were monitored by ThT, AFM, 
and DLS (Figure 4.1). In Chapter 4.2, we compared the dissociation effects by keeping the mol 
concentration of polymer chains the same. 
 
Figure 4.1 Design of experiments for dissociation of A fibrils by mP-iA5 conjugates. 
When A fibrils were coincubated with 1 equiv of 22 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the percentage of fibrils above 400 nm only decreased 
by 9% after 1 day, 13% after 2 days, and 15% after 3 days. No dissociated nanostructures were 
observed under 100 nm. The corresponding AFM images also confirmed the still existence of 
dense fibrils, although the lengths of fibrils are much shortened compared to A control. This 
finding suggests that, in the presence of low molecular weight mP-iA5 conjugate, the fibrils 
dissolution process is slow and only a small fraction of A dissociates from the fibrils (Figure 
4.2). As control, in the presence of 8.1 equiv of iAβ5 per A (8.1 equiv of iAβ5 approximately 
equal to the amount of iAβ5 copies attached to 1 equiv of 22 kDa mP-iAβ5), the preformed fibrils 
remained unchanged during 3 days of incubation according to AFM and DLS results (Figure 
4.16). To investigate the effect of the PHPMA polymer backbone on A dissociation, we 
incubated A fibrils in the presence of 1 equiv of 22 kDa control polymer with and without 8.1 
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equiv of iAβ5 for 3 days. Controls based on polymer and the mixtures of polymer with iA5 do 
not have the ability to dissolve the preformed A fibrils (Figure 4.17). 
 
Figure 4.2 Dissociation effects of 1.0 equiv of 22 kDa mP-iAβ5 conjugates on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were co-incubated with 1 equiv of 46 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the percentage of fibrils above 400 nm decreased by 
16% after 1 day, 26% after 2 days, and 46% after 3 days. The dissociated nanostructures under 
100 nm were not observed after 1 day, 26% after 2 days, and 30% after 3 days. The 
corresponding AFM images also confirmed the existence of fibrils after 1 day and 2 days, 
although the lengths of fibrils are much shortened compared to A control. The fibrils almost 
disappeared after 3 days (Figure 4.3).  As control, in the presence of 16.7 equiv of iAβ5 per A 
(16.7 equiv of iAβ5 approximately equal to the amount of iAβ5 copies attached to 1 equiv of 46 
kDa mP-iAβ5), the preformed fibrils remained unchanged during 3 days of incubation according 
to AFM and DLS results (Figure 4.18). To investigate the effect of the PHPMA polymer 
backbone on A dissociation, we incubated A fibrils in the presence of 1 equiv of 46 kDa 
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control polymer with and without 16.7 equiv of iAβ5 for 3 days. Controls based on polymer and 
the mixtures of polymer with iA5 do not have the ability to dissolve the preformed A fibrils 
(Figure 4.19). 
 
Figure 4.3 Dissociation effects of 1.0 equiv of 46 kDa mP-iAβ5 conjugates on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were co-incubated with 1 equiv of 90 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the percentage of fibrils above 400 nm remained 79% 
after 1 day, 25% after 2 days, and only 17% after 3 days. The dissociated nanostructures under 
100 nm were 21% after 1 day, 71% after 2 days, and 81% after 3 days. The corresponding AFM 
images confirmed that the fibrils decreased dramatically after 2 days, and almost all the fibrils 
were converted to the spherical nanostructures after 3 days (Figure 4.4).  As control, in the 
presence of 32.5 equiv of iAβ5 per A (32.5 equiv of iAβ5 approximately equal to the amount 
of iAβ5 copies attached to 1 equiv of 90 kDa mP-iAβ5), the preformed fibrils remained 
unchanged during 3 days of incubation according to AFM and DLS results (Figure 4.20). To 
investigate the effect of the PHPMA polymer backbone on A dissociation, we incubated A 
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fibrils in the presence of 1 equiv of 90 kDa control polymer with and without 32.5 equiv of iAβ5 
for 3 days. Controls based on polymer and the mixtures of polymer with iA5 do not have the 
ability to dissolve the preformed A fibrils (Figure 4.21). 
 
Figure 4.4 Dissociation effects of 1.0 equiv of 90 kDa mP-iAβ5 conjugates on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
The critical molecular weight of mP-iA5 conjugate to completely disassemble 
preformed A fibrils is 166 kDa. AFM images show that 1 equiv of 166 kDa mP-iA5 
efficiently induced dissociation of A fibrils into spherical nanostructures, achieving almost 
complete disassembly after 2 days. The disassembly of preformed fibrils by mP-iA5 was also 
quantitatively analyzed by DLS in solution phase. In consistence with AFM images, DLS results 
confirmed that all A fibrils are broken into nanostructures under 100 nm, and 0% of fibrils 
remains after 3 days of incubation (Figure 4.5). As control, in the presence of 60.7 equiv of iAβ5 
per A (60.7 equiv of iAβ5 approximately equal to the amount of iAβ5 copies attached to 1 
equiv of 166 kDa mP-iAβ5), the preformed fibrils remained unchanged during 3 days of 
incubation according to AFM and DLS results (Figure 4.22). To investigate the effect of the 
PHPMA polymer backbone on A dissociation, we incubated A fibrils in the presence of 1 
87 
 
equiv of 166 kDa control polymer with and without 60.7 equiv of iAβ5 for 3 days. Controls 
based on polymer and the mixtures of polymer with iA5 do not have the ability to dissolve the 
preformed A fibrils (Figure 4.23).  
 
Figure 4.5 Dissociation effects of 1.0 equiv of 166 kDa mP-iAβ5 conjugates on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were co-incubated with 1 equiv of 224 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS were similar to that when Afibrils were co-incubated with 166 
kDa mP-iA5 conjugates. The corresponding AFM images confirmed that almost all the fibrils 
were converted to the spherical nanostructures after 1 day, which is faster than the dissociation 
kinetics of the co-incubation of Afibrils and 166 kDa mP-iA5 conjugates (Figure 4.6).  As 
control, in the presence of 81.3 equiv of iAβ5 per A (81.3 equiv of iAβ5 approximately equal 
to the amount of iAβ5 copies attached to 1 equiv of 224 kDa mP-iAβ5), the preformed fibrils 
remained unchanged during 3 days of incubation according to AFM and DLS results (Figure 
4.24). To investigate the effect of the PHPMA polymer backbone on A dissociation, we 
incubated A fibrils in the presence of 1 equiv of 224 kDa control polymer with and without 
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81.3 equiv of iAβ5 for 3 days. AFM and DLS both demonstrated that the fibrils were fully 
dissociated after 2 days. It is possible that the control polymers interact with A fibrils through 
non-specific H-bonding, although the control polymers have no attached peptide sequence for 
specific interaction (Figure 4.25).  
 
Figure 4.6 Dissociation effects of 1.0 equiv of 224 kDa mP-iAβ5 conjugates on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
The AFM results on dissociation effects of 1.0 equiv of mP-iAβ5 conjugates, control 
polymer, and iA controls are summarized in Table 4.1. 
Table 4.1 AFM results summary of dissociation effects of mP-iAβ5 conjugates, control polymer, 
and iA with different molecular weights and same mol concentration of polymer chains on 
Aβ40 firbils (15 μM). 
Molecular 
Weights 
Equiv 
of iA 
mP-iAβ5 Conjugates (1.0 equiv) Control Polymer (1.0 equiv) iA 
22 kDa 8.1 Fibrils Fibrils Fibrils 
46 kDa 16.7 Short fibrils Fibrils Fibrils 
90 kDa 32.5 Nanostructures Fibrils Fibrils 
166 kDa 60.7 Nanostructures Fibrils Fibrils 
224 kDa 81.3 Nanostructures Nanostructures Fibrils 
89 
 
4.3 A Fibrils Dissociated by mP-iA5 Conjugates of Different Mn with Same mol 
Concentration of Attached Peptide 
To decouple the influence of molecular weight and the influence of the amount of 
attached LPFFD peptide on mP-iA5 conjugates, we compared the dissociation effects by 
keeping the mol concentration of attached peptide the same. We define 46 kDa conjugates as the 
standard and the mol concentration of other conjugates were calculated according to the different 
molecular weights. The mol concentration of the corresponding attached peptide is the same for 
all peptide control groups, which is 16.7 equiv. 
When A fibrils were coincubated with 2 equiv of 22 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the dissociation kinetics were much faster than that 
when A fibrils were coincubated with 1 equiv of 22 kDa mP-iA5 conjugate. The percentage 
of fibrils above 400 nm decreased by 8% after 1 day, 32% after 2 days, and 41% after 3 days. 
The dissociated nanostructures under 100 nm were not observed after 1 day, 30% after 2 days 
and 3 days. The corresponding AFM images also confirmed the existence of fibrils after 1 day 
and 2 days, although the lengths of fibrils are much shortened compared to A control. AFM 
showed a mixture of short fibrils and dissociated spherical nanostructures after 3 days (Figure 
4.7).  As control, in the presence of 16.7 equiv of iAβ5 per A (16.7 equiv of iAβ5 
approximately equal to the amount of iAβ5 copies attached to 2 equiv of 22 kDa mP-iAβ5), the 
preformed fibrils remained unchanged during 3 days of incubation according to AFM and DLS 
results (Figure 4.18). To investigate the effect of the PHPMA polymer backbone on A 
dissociation, we incubated A fibrils in the presence of 2 equiv of 22 kDa control polymer with 
and without 16.7 equiv of iAβ5 for 3 days. Controls based on polymer and the mixtures of 
polymer with iA5 do not have the ability to dissolve the preformed A fibrils (Figure 4.26). 
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Figure 4.7 Dissociation effects of 2.0 equiv of 22 kDa mP-iAβ5 conjugates on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were coincubated with 0.5 equiv of 90 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the dissociation kinetics were faster than that when 
A fibrils were coincubated with 2 equiv of 22 kDa mP-iA5 conjugate. The percentage of 
fibrils above 400 nm decreased by 19% after 1 day, 51% after 2 days, and 59% after 3 days. The 
dissociated nanostructures under 100 nm were 14% after 1 day, 42% after 2 days, and 55% after 
3 days. The corresponding AFM showed a mixture of mature fibrils and dissociated spherical 
nanostructures after 1 day, the length and amount of fibrils decreased significantly after 2 days 
and 3 days (Figure 4.8). As control, in the presence of 16.7 equiv of iAβ5 per A (16.7 equiv of 
iAβ5 approximately equal to the amount of iAβ5 copies attached to 0.5 equiv of 90 kDa mP-iAβ5), 
the preformed fibrils remained unchanged during 3 days of incubation according to AFM and 
DLS results (Figure 4.18). To investigate the effect of the PHPMA polymer backbone on A 
dissociation, we incubated A fibrils in the presence of 0.5 equiv of 90 kDa control polymer 
with and without 16.7 equiv of iAβ5 for 3 days. Controls based on polymer and the mixtures of 
polymer with iA5 do not have the ability to dissolve the preformed A fibrils (Figure 4.27). 
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Figure 4.8 Dissociation effects of 0.5 equiv of 90 kDa mP-iAβ5 conjugates on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were coincubated with 0.27 equiv of 166 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the dissociation kinetics were much faster than that 
when A fibrils were coincubated with 0.5 equiv of 90 kDa mP-iA5 conjugate. The 
percentage of fibrils above 400 nm decreased by 35% after 1 day, 55% after 2 days, and 82% 
after 3 days. The dissociated nanostructures under 100 nm were 1% after 1 day, 55% after 2 days, 
and 82% after 3 days. The corresponding AFM showed the presence of short fibrils after 1 and 2 
days, the fibrils mostly disappeared after 3 days (Figure 4.9). As control, in the presence of 16.7 
equiv of iAβ5 per A (16.7 equiv of iAβ5 approximately equal to the amount of iAβ5 copies 
attached to 0.5 equiv of 90 kDa mP-iAβ5), the preformed fibrils remained unchanged during 3 
days of incubation according to AFM and DLS results (Figure 4.18). To investigate the effect of 
the PHPMA polymer backbone on A dissociation, we incubated A fibrils in the presence 
of 0.27 equiv of 166 kDa control polymer with and without 16.7 equiv of iAβ5 for 3 days. 
Controls based on polymer and the mixtures of polymer with iA5 do not have the ability to 
dissolve the preformed A fibrils (Figure 4.28). 
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Figure 4.9 Dissociation effects of 0.27 equiv of 166 kDa mP-iAβ5 conjugates on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
When A fibrils were coincubated with 0.2 equiv of 224 kDa mP-iA5 conjugate, the 
quantitative analysis by DLS showed that the dissociation kinetics were faster than that when 
A fibrils were coincubated with 0.27 equiv of 166 kDa mP-iA5 conjugate. The percentage of 
fibrils above 400 nm decreased by 31% after 1 day, 70% after 2 days, and 94% after 3 days. The 
dissociated nanostructures under 100 nm were 4% after 1 day, 61% after 2 days, and 94% after 3 
days. The corresponding AFM showed the presence of short fibrils after 1 day, the fibrils mostly 
disappeared after 2 and 3 days (Figure 4.10). As control, in the presence of 16.7 equiv of iAβ5 
per A (16.7 equiv of iAβ5 approximately equal to the amount of iAβ5 copies attached to 0.5 
equiv of 90 kDa mP-iAβ5), the preformed fibrils remained unchanged during 3 days of 
incubation according to AFM and DLS results (Figure 4.18). To investigate the effect of the 
PHPMA polymer backbone on A dissociation, we incubated A fibrils in the presence of 
0.2 equiv of 224 kDa control polymer with and without 16.7 equiv of iAβ5 for 3 days. Controls 
based on polymer and the mixtures of polymer with iA5 do not have the ability to dissolve the 
preformed A fibrils (Figure 4.29). 
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Figure 4.10 Dissociation effects of 0.2 equiv of 224 kDa mP-iAβ5 conjugates on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
The AFM results on dissociation effects of mP-iAβ5 conjugates, control polymer, and 
iA controls are summarized in Table 4.2. 
Table 4.2 AFM results summary of dissociation effects of mP-iAβ5 conjugates, control polymer, 
and iA on Aβ40 firbils (15 μM) with different molecular weights and same mol concentration of 
attached of iA 
Molecular 
Weights 
Equiv of 
Conjugates 
mP-iAβ5 Conjugates Control Polymer iA(16.7 equiv) 
22 kDa 2.0 Fibrils Fibrils Fibrils 
46 kDa 1.0 Fibrils and nanostructures Fibrils 
90 kDa 0.5 Short fibrils and nanostructures Fibrils 
166 kDa 0.27 Short fibrils and nanostructures Fibrils 
224 kDa 0.2 Nanostructures Fibrils 
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4.4 Hypothesis of Dissociation Mechanism and Rate Equations 
We demonstrate that synthetic multivalent polymer-peptide conjugates are an effective 
strategy to dissociate preformed A fibrils, and the molecular weight is the key criterion that 
determines the dissociation rate. Table 4.1 and 4.2 show a collection of quantitative results from 
dissociation study monitored by DLS during 3 days incubation. 
We speculate mP-iA5 conjugates create a high local concentration of LPFFD by 
localizing sufficient LPFFD peptide copies in the unit volume, and mP-iA5 conjugates compete 
with A peptide, interacting with A fibrils through multiple -sheet interaction,. The A 
fibrils are disrupted when the molecular weight of conjugates is high enough so that A-
conjugates binding overcome A-A binding due to the concentration effect. We cannot rule out 
the possibility that mP-iA5 conjugates bind to A monomer and oligomers thus shifting the 
equilibrium between monomeric A peptide and A fibrils. However, A dissociation is 
not accompanied by the decreased ThT intensity, which indicates that the dissociated A still 
preserve -sheet structure. The -sheet structure of dissociated A protein was also confirmed 
by circular dichroism. Thus, it is less likely the conjugates dissociate A fibrils by binding to 
A monomer and oligomers, in which case the dissociated A would preserve random coil 
structures as previously suggested. 
According to this hypothesis, the rate equation of dissociation is expressed as: 
r = kMn[A]
x
[B]
y
   …(1) 
Where [A] is the concentration of A40 fibrils (>400 nm). There is no absolute concentration, so 
we use the relative concentration from DLS studies.  
[B] is the total concentration of attached peptide iA5. [B] = number of iA5 copies on each 
polymer * mol concentration of mP-iA5. 
kMn is the rate constant, which is determined by molecular weight of mP-iA5 conjugates. 
When the total concentration of attached peptide was kept constant, the mP-iA5 conjugates of 
higher molecular weight dissociate A40 fibrils with a faster rate, which indicate that mP-iA5 
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conjugates increase the local concentration of iA5 by multivalent effect. The multivalent effect 
alters the rate constant kMn in a molecular weight dependent manner. 
The concentration of attached peptide iA5 is the same order as the concentration of A40 
monomer, which is much higher than the concentration of A40 fibrils. [B0]>>[A0], and the 
concentration change of iA5 is negligible during the reaction. Thus, the rate equation is 
modified as:  
r = kMn[A]
x
[B0]
y
 …(2) 
The first step is the determination of x, the reaction order of amyloid fibrils by keeping 
the concentration of iA5 constant. We use DLS to monitor the concentration change of A40 
fibrils and the data are summarized in Table 4.3. 
Table 4.3 Dissociation effects of 1.0 equiv of mP-iAβ5 conjugates with different molecular 
weights on pre-incubated Aβ40 (15 μM) fibrils monitored by DLS over 3 days. Percentage of 
remaining A40 fibrils above 400 nm and dissociated A40 under 100 nm.  
Molecular 
Weights 
Day 1 Day 2 Day 3 
>400 nm <100 nm >400 nm <100 nm >400 nm <100 nm 
22 kDa 91% 0% 87% 0% 85% 0% 
46 kDa 84% 0% 74% 26% 54% 30% 
90 kDa 79% 21% 25% 71% 17% 81% 
166 kDa 12% 87% 5% 94% 0% 100% 
224 kDa 8% 92% 2% 97% 0% 100% 
 
r22 = k22[B0]
y
 [A]
x
 …(3) 
r46 = k46[B0]
y
 [A]
x
 …(4) 
r90 = k90[B0]
y
 [A]
x
 …(5) 
r166 = k166[B0]
y
 [A]
x
 …(6) 
r224 = k224[B0]
y
 [A]
x
 …(7) 
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To determine x, we plot [A]~t (zero-order reaction), ln[A]~t (first order reaction), and 
1/[A]~t (second order reaction). The data has the best fit in linear regression when we plot 
ln[A]~t (Figure K2), so x = 1. 
 
Figure 4.11 Linear regression of ln[A]~t when the amount of attached iAβ5 is kept constant.  
x = 1, the rate equations are modified as: 
r22 = k22[B0]
y
 [A] …(8) 
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r46 = k46[B0]
y
 [A] …(9) 
r90 = k90[B0]
y
 [A] …(10) 
r166 = k166[B0]
y
 [A] …(11) 
r224 = k224[B0]
y
 [A] …(12) 
The slope from linear regression (SMn) = -kMn[B0]
y
  …(13) 
Where [B0] is a constant in the above studies, kMn is a function of molecular weight. 
kMn = f(Mn) 
To determine the relation between kMn and Mn, we plot SMn vs. Mn  
 
 
Figure 4.12 Binomial regression of SMn ~ Mn when the amount of attached iAβ5 is kept constant. 
Figure 4.12 indicate that SMn have binomial relations with Mn when [B0] is kept as a 
constant. Thus, kMn have binomial relations with Mn. The regression equation from Figure 4.12 
is qualitative because reaction order of y is not determined yet. 
To determine y, we use the DLS data in the experimental group when the mol 
concentration of mP-iA5 conjugates are kept constant (Table 4.4).  
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Table 4.4 Dissociation effects of mP-iAβ5 conjugates with different molecular weights and same 
amount of attached peptide on pre-incubated Aβ40 (15 μM) fibrils monitored by DLS over 3 days. 
Percentage of remaining A40 fibrils above 400 nm and dissociated A40 under 100 nm.  
Molecular 
Weights 
Equiv of 
Polymer 
Equiv of 
Attached 
iA5 
Day 1 Day 2 Day 3 
>400 nm <100 nm >400 nm <100 nm >400 nm <100 nm 
22 kDa 2.0 16.7 92% 0% 68% 30% 59% 29% 
46 kDa 1.0 16.7 84% 0% 74% 26% 54% 30% 
90 kDa 0.5 16.7 81% 14% 49% 42% 41% 55% 
166 kDa 0.27 16.7 65% 1% 45% 55% 18% 82% 
224 kDa 0.2 16.7 69% 4% 30% 61% 6% 94% 
 
In this group of study, [B0] = number of iAβ5 per chain (n) * mol concentration of mP-
iA5 conjugates (m). According to the data shown in Table 4.5,  n = 0.364Mn, m = 15 M, [B0, 
Mn] = 0.364Mn * 15 M. 
Table 4.5 Degree of polymerization and number of iAβ5 per chain of mP-iA5 conjugates with 
different molecular weights. 
Molecular Weight Loading Ratio Degree of 
Polymerization 
Number of iAβ5 
per Chain 
22 kDa 
46 kDa 
90 kDa 
166 kDa 
224 kDa 
7% 
7% 
7% 
7% 
7% 
116 
239 
464 
867 
1161 
8.1 
16.7 
32.5 
60.7 
81.3 
 
The rate equations of Table 4.4 are represented as: 
r
’
22 = k22[B0,22]
y
 [A]  …(14) 
r
’
46 = k46[B0,46]
y
 [A]  …(15) 
r
’
90 = k90[B0,90]
y
 [A]  …(16) 
r
’
166 = k166[B0,166]
y
 [A] …(17) 
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r
’
224 = k224[B0,224]
y
 [A] …(18) 
Plot ln[A]~t as shown in Figure K3, the slope (S
’
Mn) = - k22[B0,Mn]
y
.  …(19) 
 
Figure 4.13 Linear regression of ln[A]~t when the mol concentration of mP-iAβ5 is kept constant. 
According to equation (19), the slope from linear regression (S
’
Mn) = -kMn[B0,Mn]
y
 
To determine the reaction order of y, we plot S
’
Mn vs. Mn. 
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Figure 4.14 Trinomial regression of S
’
Mn ~ Mn when the mol concentration of mP-iAβ5 is kept 
constant. 
We proved that [B0,Mn] = 0.364Mn * 15 M, and kMn have binomial relations with Mn. 
From the equation (19) S
’
Mn = -kMn[B0,Mn]
y
, y is determined as 1. 
To solve kMn = f(Mn), we bring the value of y back to equation (13) 
SMn = -kMn[B0]
y
 is modified as SMn = -kMn[B0] …(20) 
[B0] = 16.7 * 15 M = 250.5 M 
SMn = -kMn[B0] = - 2.5E-04*kMn   …(21) 
According to the regression equation from Figure 4.12,  
SMn = -1.045E-05(Mn)
2
 - 5.169E-04 (Mn) - 0.1552   …(22) 
Simultaneous equations of (21) and (22), kMn = 4.18E-02(Mn)
2 
+ 2.07Mn + 621 …(23) 
Equation (23) only indicates that kMn has binomial relationship with Mn. Theoretically, 
k=Aexp(-Ea/RT). Thus, mP-iAβ5 conjugates of higher molecular weights have lower Ea due to 
multivalent effect. 
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Figure 4.15 Reaction coordinate of A40 fibrils dissociation reaction.  
In conclusion, the rate equation of dissociation is determined as: 
r = kMn[B0] [A] 
Where kMn is dependent on Mn in a binomial manner. 
 
4.5 Experimental Details 
4.5.1 Materials and General Methods  
Materials. Thioflavin T (ThT, dye content, ~75%) was purchased from Sigma-Aldrich and used 
as received. Amyloid  protein (A40) was purchased from GL Biochem Ltd. (Shanghai, China). 
Pentapeptide LPFFD (iA5) was purchased from American Peptide. Molecular biology grade 
water (ultrapure water) for ThT Assays was purchased from Corning. PBS buffer (100 mM) was 
purchased from Lonza.  All other solvents (HPLC or spectroscopic grade) were purchased from 
Sigma-Aldrich or Fisher, and used as received. 
Atomic Force Microscopy (AFM). Samples for AFM studies were taken directly from the ThT 
assays, and 10 L of each sample solution was loaded on freshly cleaved mica surface (Electron 
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Microscopy Sciences, catalog NO. 71856-01). Samples were incubated for 5 minutes and rinsed 
with 5 drops of molecular biology grade water. The mica surface was blow-dried under nitrogen. 
AFM images were obtained on a MultiMode V (Bruker, Santa Barbara, USA) microscope in 
tapping mode. Ultrasharp silicon cantilevers (SCANASYST-ATR, Bruker) were used. All of the 
images were collected at a scan rate of 1 Hz and scan lines of 512. 
Dynamic Light Scattering (DLS). Samples for DLS studies were prepared at the same condition 
as in ThT assays without adding ThT dye molecules. The DLS studies were carried out using a 
particle sizer NICOMP 380 ZLS.   
4.5.2 Effects of Control Groups on Preformed A Fibrils 
The effects of control polymer and iAβ5 free peptide on preformed Aβ fibrils have been 
discussed in Chapter 4.3. Here we show the detailed data of AFM and DLS.   
 
Figure 4.16 Dissociation effects of 8.1 equiv of LPFFD (8.1 equiv of LPFFD approximately 
equal to the amount of LPFFD copies attached to 1 equiv of 22 kDa mP-iAβ5) on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.17  Dissociation effects of 1.0 equiv of 22 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.18 Dissociation effects of 16.7 equiv of LPFFD (16.7 equiv of LPFFD approximately 
equal to the amount of LPFFD copies attached to 1 equiv of 46 kDa mP-iAβ5) on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.19 Dissociation effects of 1.0 equiv of 46 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.20 Dissociation effects of 32.5 equiv of LPFFD (32.5 equiv of LPFFD approximately 
equal to the amount of LPFFD copies attached to 1 equiv of 90 kDa mP-iAβ5) on pre-incubated 
Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), 
and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.21 Dissociation effects of 1.0 equiv of 90 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.22 Dissociation effects of 60.7 equiv of LPFFD (60.7 equiv of LPFFD approximately 
equal to the amount of LPFFD copies attached to 1 equiv of 166 kDa mP-iAβ5) on pre-
incubated Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 
days (b,b’), and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.23 Dissociation effects of 1.0 equiv of 166 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.24 Dissociation effects of 81.3 equiv of LPFFD (81.3 equiv of LPFFD approximately 
equal to the amount of LPFFD copies attached to 1 equiv of 224 kDa mP-iAβ5) on pre-
incubated Aβ40 (15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 
days (b,b’), and 3 days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.25 Dissociation effects of 1.0 equiv of 224 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.26 Dissociation effects of 2.0 equiv of 22 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.27 Dissociation effects of 0.5 equiv of 90 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
 
Figure 4.28 Dissociation effects of 0.27 equiv of 166 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
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Figure 4.29 Dissociation effects of 0.2 equiv of 224 kDa control polymer on pre-incubated Aβ40 
(15 μM) fibrils monitored by AFM (top) and DLS (bottom) over 1 day (a, a’), 2 days (b,b’), and 3 
days (c, c’). We define equiv as molar ratio of mP-iAβ5 conjugates to Aβ40. 
4.5.3 Thioflavin T Fluorescence Assays  
ThT fluorescence assays were conducted in 96-well black plate (Thermo Scientific 
NUNC, catalog NO. 265301) at 37 
o
C with continuous shaking (567 rpm) in a BioTek Hybrid 
H1 plate reader. ThT fluorescence was recorded with 10 minutes reading intervals and 5 s 
shaking before first read (442 nm excitation, 482 nm emission). All samples were run in 
quadruple or more. At least three independent experiments were carried out for each ThT assay. 
Each well contained 10 mM PBS buffer solution (pH 7.4) and 20 µM ThT in a total volume of 
200 L. Aβ40 (15 µM, 1.0 equiv), iA5, control polymer 5, and mP-iA5 conjugates 4 were 
added as needed. The concentrations of added samples were calculated based on A40 (15 µM, 
1.0 equiv). 
To each well of 96-well plate, the buffered ThT solution (40 M, 100 L) and ultrapure 
water (80 L) were added and mixed. Then A40 solution (150 M, 20 L) was added. The 
samples of pure A40 were incubated for 24 h to form mature fibrils. Then mP-iA5 conjugates, 
control polymer, and LPFFD were dissolved in ultrapure water to 10 times concentrated as 
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needed concentration in ThT assays. The above concentrated solutions of modulators (20 L) 
were added to the wells containing 200 L of pre-incubated A40solutions to reach the needed 
concentration. The samples containing mature fibrils of A40 and modulators were coincubated 
for another 3 days in plate reader. The fluorescence was monitored by ThT assays (Figure 4.25-
4.33). A40 dissociation is not accompanied by the decreased ThT intensity, which indicates that 
the dissociated A40 still preserve -sheet structure. The -sheet structure of dissociated A40 
protein was also confirmed by circular dichroism. 
 
Figure 4.30 Effects of 22 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (8.1 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C.  
 
Figure 4.31 Effects of 46 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (16.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
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Figure 4.32 Effects of 90 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (32.5 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
 
Figure 4.33 Effects of 166 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 equiv), and 
iA5 (60.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
 
Figure 4.34  
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Figure 4.34 (cont.) Effects of 224 kDa mP-iA5 conjugates (1.0 equiv), control polymer (1.0 
equiv), and iA5 (81.3 equiv) on A40 dissociation monitored by ThT assays. We define equiv as 
the molar ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 
M A40 peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
 
Figure 4.35 Effects of 22 kDa mP-iA5 conjugates (2.0 equiv), control polymer (2.0 equiv), and 
iA5 (16.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
 
Figure 4.36 Effects of 90 kDa mP-iA5 conjugates (0.5 equiv), control polymer (0.5 equiv), and 
iA5 (16.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
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Figure 4.37 Effects of 166 kDa mP-iA5 conjugates (0.27 equiv), control polymer (0.27 equiv), 
and iA5 (16.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the 
molar ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M 
A40 peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
 
Figure 4.38 Effects of 224 kDa mP-iA5 conjugates (0.2 equiv), control polymer (0.2 equiv), and 
iA5 (16.7 equiv) on A40 dissociation monitored by ThT assays. We define equiv as the molar 
ratio of mP-iA5 conjugates or iA5 peptide to A40. ThT assays were performed on 15 M A40 
peptide in PBS buffer (pH 7.4) at 37 C with shaking (567 rpm).  
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Chapter 5: Molecular Design for Dual Modulation Effect of A Aggregation 
5.1 Introduction 
To control amyloid aggregation, modulation of various steps of fibrillar growth provides 
a promising strategy.
1,2
 Modulators of fibrillar growth can regulate final size and shape of non-
covalent protein assemblies, while potentially transforming the cytotoxic properties of the 
aggregation products.
3,4
 The current modulation of amyloid aggregation by modulators mainly 
includes inhibition and acceleration, as summarized below. 
Inhibition has been an effective strategy to modulate the process of amyloid aggregation.
5
 
Inhibitory modulation is usually used to prevent amyloid fibril formation and thus reduce 
cytotoxic effects of amyloid aggregates. Many inhibitory modulators, including small molecule-, 
peptide-, nucleic acid-, antibody-, and nanomaterial-based inhibitors, have been developed and 
studied.
 6-9
 By controlling amyloid aggregation, researchers will have the tools to elucidate the 
molecular etiology of disease associated with protein aggregation in in vitro studies.
10
 
Recently, acceleration has become a promising strategy to modulate the process of 
amyloid aggregation.
11
 The Wanker group demonstrated that the orcein-related small molecule 
O4 stabilizes the aggregated A intermediates and promotes the aggregation process.11 
Consequently, the accelerated removal of A aggregates converts toxic A oligomers to 
nontoxic Afibrils. This seminal work showed that acceleration has a clearing capability with 
therapeutic potential. It is clear that inhibitory and acceleratory modulation have provided 
powerful approaches to understand and control amyloid protein aggregation. However, these are 
the only two modulation approaches known at present. 
Attempts to develop new modulation approach involve a promising design of 
multifunctional modulators which target multiple regions on amyloid proteins.
12
 However, 
multifunctional modulators have rarely been reported to target different phases along amyloid 
protein aggregation pathway. Here, we provide evidence for a new multifunctional modulation 
concept, a dual modulation that includes both acceleration and inhibition of amyloid aggregation. 
We synthesized the polyethyleneimine-perphenazine (PEI-P) conjugate which has a dual 
“acceleration-inhibition” modulation effect on amyloid  (A) aggregation. Thioflavin T (ThT) 
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fluorescence, atomic force microscopy (AFM), and circular dichroism (CD) studies show that 
PEI-P conjugates accelerate formation of A prefibrillar intermediates and then inhibit 
Afibrillation. Furthermore, compared to perphenazine alone, PEI-P conjugates exhibit an 
enhanced inhibitory effect due to multivalency. Compared to the simple inhibition or 
acceleration, this dual modulation presents an alternative strategy to stabilize transient 
intermediates, which may shed light on mechanism studies on amyloid aggregation as well as 
potential foundation to investigate the pathogenic species formed from aggregation pathway.  
5.2 Design and Synthesis of Dual-Effect Modulators  
The polyethyleneimine-perphenazine conjugates with a PEI core (Mn: 600, Mw: 800) 
attached to multiple copies of perphenazine inhibitors were rationally designed to achieve the 
dual-effect on A aggregation (Figure 5.1). Recent work shows that cellular polyamines, a 
family of small molecule polycationic alkylamines, accelerate A aggregation by targeting 
negatively charged N-terminus of A protein (Figure 5.1a, marked in red).13 In addition, 
positively charged PEIs were also reported to accelerate α-synuclein fibrillation associated with 
Parkinson’s disease.14 Analogously, we expected that the PEI core will also accelerate A 
aggregation. Perphenazine, an aromatic small molecule, is a known inhibitor of A aggregation, 
so we envisioned that attachment of perphenazines to the periphery will inhibit A aggregation 
via targeting hydrophobic residues of A sequences (LVFFA).15 
 
Figure 5.1  
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Figure 5.1 (cont.) Design and synthesis of polyethyleneimine-perphenazine conjugates. (a) 
Amino acid sequences of A40 in which the negatively charged amino acid residues at pH 7.4 are 
in red, while the central hydrophobic residues are in green. Design of PEI-P conjugates in which 
the positively charged PEI core at pH 7.4 is in red, while the peripheral perphenazines are in 
green. (b) Synthesis of PEI-P conjugates. 
The PEI-P conjugates were prepared in two steps (Figure 5.1b). Perphenazine-acrylate 
was first synthesized by the nucleophilic substitution of the acryloyl chloride with perphenazine. 
Michael addition of the perphenazine-acrylate to the commercially available branched PEI, 
containing, on average, 14 repeating units of [CH2CH2NH] produced conjugates with a molar 
ratio of 4.5:1 (moles of perphenazine-acrylate per mole PEI oligomer). The composition was 
determined by NMR. We use the notation PEI-P-4.5 to designate the small molecule loading of 
the conjugate. 
5.3 Modulation of A Aggregation by PEI, Perphenazine, and PEI-P Conjugates 
To investigate the modulation eﬀects of PEI, perphenazine, and PEI-P-4.5 on A40 
aggregation, we used the lag phase measured by ThT fluorescence assays to first evaluate their 
activities against A40 (15 M) aggregation.
16
 AFM studies were used to corroborate the results 
from the ThT assays. The ThT assays show that PEI accelerates A40 aggregation by 44% at 0.13 
equiv (i.e. molar ratio of PEI oligomer to A40), decreasing the lag time from 190 min to 105 
min, and by 58% at 1.3 equiv, decreasing the lag time from 190 min to 80 min (Figure 5.2b). 
These results indicate that the acceleratory effect of PEI is not strongly dose-dependent. 
Surprisingly, AFM studies of samples taken from the ThT assays show that PEI accelerates 
formation of disordered aggregates, rather than long unbranched mature fibrils (Figure 5.2e). 
These results suggest that PEI interacts with A40 or A40 aggregates to alter the association of 
A40 monomers that would otherwise lead to final fibril formation. The above results 
demonstrate that PEI first accelerates the early structural transformation of prefibrillar A40 
intermediates and then redirects A40 aggregation to form disordered aggregates. 
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Figure 5.2 ThT fluorescence assays and AFM images. (a) Fibrillation kinetics of A40 (15 M) 
monitored by a ThT fluorescence assay. ThT fluorescence assays of A40 aggregation with 19.5 
M of PEI, 1.3 equiv (b), and 90 μM of perphenazine, 6 equiv (c). ThT assays were performed on 
15 μM A40 peptide in HEPES buffer (pH 7.4) at 37 °C. For clarity of the lag phase, the ThT 
fluorescence assay data in (a)-(c) are plotted only for the first 10 h out of the full time course (67 
h). AFM images of A40 (15 M) after incubation for 3.3 h, 20 h, and 67 h without modulators 
(d), and with 19.5 M of PEI, 1.3 equiv (e), and 90 M of perphenazine, 6 equiv (f). Samples for 
AFM studies were taken directly from the ThT assays. Image size is 10 × 10 m. We define equiv 
as molar ratio of PEI oligomer or perphenazine to A40. 
ThT assays also show that perphenazine inhibits A40 aggregation in a dose-dependent 
manner. For example, perphenazine does not significantly affect A40 aggregation at 0.6 equiv, 
but delays A40 aggregation at 6 equiv (Figure 5.2c). These results are confirmed by the AFM 
studies (Figure 5.2f). AFM images show that A40 forms fibrils in the presence of perphenazine 
(0.6 equiv), indicative of no significant effect on A40 fibrillation. A40 does not form fibrils in 
the presence of perphenazine (6 equiv) after 20 h incubation during the delayed lag time, 
indicative of inhibition of A40 fibrillation (Figure 5.2f, middle). However, the prefibrillar A40 
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intermediates stabilized by perphenazine (6 equiv) eventually yield fibril formation after 67 h of 
incubation (Figure 5.2f, bottom). 
Interestingly, ThT fluorescence assays and AFM studies indicate that the PEI-P-4.5 
conjugate modulates A40 aggregation in a dose-dependent manner (Figure 5.3b and 5.3c). PEI-
P-4.5 at the lower concentration (0.13 equiv, define as the molar ratio of PEI-P-4.5 oligomer to 
A40) exhibits a dual-effect on modulation of A40 aggregation, while PEI-P-4.5 at the higher 
concentration (1.3 equiv) acts more like an inhibitor. ThT fluorescence assays show that PEI-P-
4.5 (0.13 equiv) accelerates A40 aggregation by 41%, decreasing the lag time from 190 min to 
110 min (Figure 5.3b). The acceleration effect of PEI-P-4.5 is similar to that of PEI. However, 
unlike the promotion of the off-pathway A40 aggregation by PEI, AFM studies indicate that 
PEI-P-4.5 promotes an on-pathway aggregation which ultimately leads to fibrillation (Figure 
5.3e). These results provide evidence that PEI-P-4.5 at the low concentration is able to accelerate 
the formation of the prefibrillar A40 intermediates and delay A40 fibrillation. It is suggested 
that the prefibrillar A40 intermediates promoted by PEI-P-4.5 (0.13 equiv) and PEI (0.13 equiv) 
are different because one is on the pathway of A40 fibrillation, while the other is not. ThT 
assays also show that the fibrillation kinetics of A40 aggregation with PEI-P-4.5 (1.3 equiv) 
does not shorten the lag time which is indicative of an acceleration effect; instead, it exhibits a 
delayed lag phase (Figure 5.3c). AFM studies confirm that A40 does not form fibrils in the 
presence of PEI-P-4.5 (1.3 equiv) even after 67 h incubation (Figure 5.3e). 
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Figure 5.3 ThT fluorescence assays and AFM images. (a) Fibrillation kinetics of A40 monitored 
by a ThT fluorescence assay. ThT fluorescence assays of A40 aggregation with 1.95 M of PEI-
P-4.5, 0.13 equiv (b), and 19.5 M of PEI-P-4.5, 1.3 equiv (c). ThT assays were performed on 15 
M A40 peptide in HEPES buffer (pH 7.4) at 37 °C. For clarity of the lag phase, the ThT 
fluorescence assay data in (a)-(c) are plotted only for the first 10 h out of the full time course (67 
h). AFM images of A40 (15 M ) after incubation for 3.3 h, 20 h, and 67 h without modulators 
(d), and with 1.95 M of PEI-P-4.5, 0.13 equiv (e), and 19.5 M of PEI-P-4.5, 1.3 equiv (f). 
Samples for AFM studies were taken directly from the ThT assays. Image size is 10 × 10 m. We 
define equiv as the molar ratio of PEI-P-4.5 oligomer to A40. 
To quantitatively monitor the amount of protein that has aggregated (aggregates >30 
kDa), we filtered the Aβ40 solutions through filters having a 30 kDa cutoff and determined the 
protein concentration by a BCA protein assay (Figure 5.4).  
 
When A40 is co-incubated with 1.3 equiv of PEI and PEI-P-4.5, the concentration of 
monomer and small oligomers decrease dramatically over the incubation time, which indicate the 
acceleration effect of PEI and PEI-P-4.5 on A40 aggregation. After 0.5 h incubation, in the 
presence of 1.3 equiv PEI and PEI-P-4.5, the aggregated fraction of A40 (>30 kDa) reach 61.5% 
and 56.4%, while the aggregated fraction of A40 (>30 kDa) alone only arrives 16.3%. The 
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results above demonstrate the initial acceleration effect of PEI and PEI-P-4.5. Meanwhile, even 
after 24 h incubation, the aggregated fraction of A40 (>30 kDa) only arrives 19.4% when A40 
is co-incubated with 6 equiv of perphenazine, which indicates the inhibitory effect of 
perphenazine. 
 
Figure 5.4 Fraction aggregated  (>30 kDa) assay of A40 alone and A40 co-incubated with PEI, 
PEI-P-4.5 at 1.3 equiv, or perphenazine at 6 equiv under different incubation time at pH 7.4. 
5.4 Modulation of A Aggregation by PEI-P Conjugates with Different Loadings of 
Perphenazine  
To investigate how the inhibitory periphery of PEI-P conjugates affect A40 aggregation, 
we synthesized two more conjugates with different loading ratios. According to the 
characterization by NMR studies, these PEI-P conjugates have an average 1.5 and 3.0 
perphenazine unit per PEI chain designated as PEI-P-1.5 and PEI-P-3.0 respectively. 
ThT fluorescence assays and AFM studies indicate that the perphenazine loading affects 
modulation of A40 aggregation by the PEI-P conjugates (Figure 5.5). The ThT assays show that 
PEI-P-1.5, PEI-P-3.0, and PEI-P-4.5 accelerate A40 aggregation by 52%, 57%, and 54% at 0.13 
equiv, decreasing the lag time from 198 min to 96, 86 and 92 min, respectively (Figure 5.5a). 
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Although the ThT assays show the acceleratory effects of all PEI-P conjugates, the AFM studies 
indicate that PEI-P-1.5 redirects A40 aggregation to form disordered aggregates as PEI does 
(Figure 5.5c), while PEI-P-3.0  leads to fibrillation of A40 similar to aforementioned PEI-P-4.5 
(Figure 5.5d and 5.4e). AFM studies confirm that A40 does not form fibrils in the presence of 
PEI-P-3.0 or PEI-P-4.5 at 1.3 equiv (Figure 5.5d’ and 5.5e’), while A40 forms disordered 
aggregates in the presence of 1.3 equiv PEI-P-1.5 (Figure 5.5c’). The above results suggest that 
PEI-P-1.5 redirect A40 aggregation as PEI does, while PEI-P-3.0 behaves more like PEI-P-4.5. 
   
Figure 5.5 Lag time of A40 aggregation without or with modulators monitored by ThT 
fluorescence assays (a). ThT assays were performed on 15 M A40 peptide in HEPES buffer 
(pH 7.4) at 37°C with a shaking speed of 567 rpm. AFM images of A40 (15 M) after incubation 
for 20 h without modulators (b), and with 1.95 M of PEI-P-1.5 after incubation for 20 h, 0.13 
equiv (c), 1.95 M of PEI-P-3.0 after incubation for 20 h, 0.13 equiv (d), 1.95 M of PEI-P-4.5 
after incubation for 20 h, 0.13 equiv (e), 19.5 M of PEI-P-1.5 after incubation for 20 h, 1.3 
equiv (c’), 19.5 M of PEI-P-3.0 after incubation for 20 h, 1.3 equiv (d’), 19.5 M of PEI-P-4.5 
after incubation for 20 h, 1.3 equiv (e’)  Samples for AFM studies were taken directly from the 
ThT assays. Image size is 10 × 10 m. We define equiv as the molar ratio of PEI-P-1.5 oligomer, 
PEI-P-3.0 oligomer or PEI-P-4.5 oligomer to A40.  
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5.5 Hypothesis on the Dual Modulatory Effects of PEI-P Conjugates 
Our studies indicate that the PEI core has the ability to accelerate the formation of the 
prefibrillar A40 intermediates and redirect the aggregation process to form off-pathway 
disordered aggregates, while perphenazine has the ability to stabilize the on-pathway prefibrillar 
intermediates, leading to the final fibrils and delay on pathway aggregation (Figure 5.6). It can be 
imagined that PEI-P conjugates should have the ability to accelerate, redirect, and delay A40 
aggregation. Furthermore, the stabilizing and inhibitory abilities of PEI-P conjugates from 
perphenazine should be enhanced because of the multivalent effect. Accordingly, the loading-
dependent and dose-dependent dual-effect of PEI-P conjugates on A40 aggregation may come 
from the interplay of the abilities of acceleration (PEI), redirection (PEI), enhanced stabilization 
(perphenazine and multivalency), and enhanced inhibition (perphenazine and multivalency).  
It is surprising that the PEI-P conjugates with high loading of perphenazine exhibit an on-
pathway dual-effect on A40 aggregation, leading to the formation of A40 fibrils, while 
exhibiting an off-pathway dual-effect for PEI-P conjugates with low loading of perphenazine, 
entirely redirecting the aggregation process to form disordered A40 aggregates, which may due 
to the dominated effect of PEI core (Figure 5.6b).  
PEI-P conjugates successfully lead to a dual “acceleration-inhibition” modulation effect 
on A aggregation. This observed dual-effect comprises acceleration of the Aβ intermediate 
formation and inhibition of A fibrillation, resulting from the combination of the acceleration 
and inhibition in PEI-P conjugates. Our studies show that the perphenazine loading and the 
concentration of the PEI-P conjugates play two key factors for the overall modulation of Aβ 
aggregation. We envision that the concept described herein could be generalized to other 
structures that exhibit two modes of modulating A aggregation and other amyloid proteins. 
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Figure 5.6 Cartoon representation summarizing modulation of A40 aggregation by the PEI-P 
conjugates, PEI, and perphenazine. (a) On-pathway inhibition of A40 aggregation by 
perphenazine and off-pathway acceleration of A40 aggregation by PEI. (b) Loading-dependent 
modulation of A40 aggregation by the PEI-P conjugates. 
5.6 Experimental Details 
5.6.1 Materials and Methods 
Materials. Polyethyleneimine, branched (Mn~600 determined by GPC, Mw~800 determined by 
LS), acryloyl chloride,pyridine (anhydrous, 99.8%), perphenazine and Thioflavin T (ThT, dye 
content, ~75%) were purchased from Sigma-Aldrich. -Amyloid protein (A40) was from GL 
Biochem Ltd. (Shanghai, China). Anhydrous tetrahydrofuran were from Fisher and purified 
before use. Water (molecular biology grade) for ThT Assays and biological experiments was 
obtained from Corning. A CellTiter 96 non-radioactive cell proliferation assay kit, 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay, was purchased from 
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Promega (catalog No. G4000). Pierce
®
 BCA Protein Assay Kit and 30 kDa Centricon filters 
were purchased from Fisher. All other solvents (HPLC or spectroscopic grade) were purchased 
from Sigma-Aldrich or Fisher and used as received. 
Nuclear Magnetic Resonance
 
(NMR). 
1
H and 
13
C NMR spectra were recorded on a Varian U500 
MHz spectrometer using deuterated chloroform as solvent. 
Atomic Force Microscopy (AFM). AFM measurements were performed on a MultiMode V 
(Bruker, Santa Barbara, USA) microscope in tapping mode under ambient conditions. Ultrasharp 
silicon cantilever (SCANASYST-ATR, Bruker) with a resonance frequency of 50-90 KHz, a 
spring constant of 0.4 N m
-1
, and a normal tip radius of 15 nm or 30 nm were chose to image the 
samples. All of the images were collected at a scan rate of 1 Hz. Aβ40 samples were taken 
directly from the ThT assays incubated with for different time intervals (3.3 h, 20 h and 67 h 
respectively) and 10 L of each sample solution was deposited on freshly prepared mica surface. 
After incubated for 10 min, the surface was washed by water (molecular biology grade) and 
dried under nitrogen flow. 
BCA Protein Assays. Sample incubation were conducted in 96-well black plate at 37 

C with 
continuous shake (shaking speed: Middle) in a BioTek Hybrid H1 plate reader. The samples 
were taken out directly at different time intervals (0 h, 0.5 h, 1.5 h, 3 h, 5 h 7 h, 10 h and 24 h) 
and filtered by 30 kDa Centricon filters (12000 rpm for 10 minutes) to remove aggregates. Then, 
the concentration of A40 protein was determined by Pierce
®
 BCA Protein Assay Kit at 25 
o
C 
following microplate procedure. 
Preparation of samples by BCA Protein Assay Kit. 
(1) Pipette 25 µL of each sample replicate into a microplate well. 
(2) Working Reagent is freshly prepared. Prepare Working Reagent by mixing 50 parts of BCA 
Reagent A with 1 part of BCA Reagent B (50:1, Reagent A:B). 
(3) Add 200 µL of the Working Reagent to each well and mix plate thoroughly on a plate shaker 
for 30 seconds. 
(4) Cover plate and incubate the samples at 60 °C for 30 minutes. 
(5) Cool plate to room temperature and measure the absorbance of the samples at 562 nm on a 
BioTek Hybrid H1 plate reader. 
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5.6.2 Synthesis of PEI-P Conjugates 
 
2-[4-[3-(2-chloro-10H-phenothiazin-10-yl) propyl] piperazin-1-yl] acrylate (perphenazine-
acrylate):  Perphenazine (0.504 g, 1.251 mmol), Pyridine (0.395 g, 5 mmol) and THF (15 mL) 
was added to a 25 mL three-necked round bottom flask equipped with a magnetic stirrer and 
purged with N2. The above solution was cooled in an ice water bath, and acryloyl chloride (0.450 
g, 5 mmol) was added dropwise under nitrogen.  The mixture was stirred overnight at room 
temperature. Then the solvent was removed through a rotavapor under reduced vacuum and dried 
under a high vacuum system to yield a sticky yellowish oil.  The oil was re-dissolved in 
dichloromethane (40 mL) and washed with DI water, HCl (0.1 M, 20 mL), saturated NaHCO3 
(20 mL), saturated NaCl (20 mL) and dried by anhydrous Na2SO4.  The solvent was removed 
under vacuum, yielding perphenazine-acrylate (0.444 g, 77.7%) as sticky yellowish oil: 
1
H NMR 
(500 MHz, CDCl3) δ 7.16~6.86 (Benzene ring, 7H), 6.43, 6.39 (d, CH2=CH, 1H), 6.17, 6.11 (dd, 
CH2=CH, 1H), 5.84, 5.82 (d, CH2=CH, 1H), 4.27 (t, COO-CH2, 2H), 3.92 (t, Benzene-NCH2, 
2H), 2.68 (COO-CH2CH2, 2H), 2.48 (br, CH2 of piperazin, piperazin-CH2CH2CH2N, 10 H) 1.95 
(br, piperazin-CH2CH2CH2N, 2H); 
13
C NMR (500 MHz, CDCl3) δ 166.3, 146.7, 144.7, 133.4, 
131.0, 128.7, 128.1, 127.7, 124.9, 123.7, 123.1, 122.4, 116.0, 62.3, 56.8, 55.7, 53.7, 53.5, 45.6, 
24.5; HR-MS (ESI
+
): m/z (%): 458.2 (100), 460.2 (40.5), 461.2 (10.5); Calc for C24H28ClN3O2S 
(M + H)
+ 
(m/z)  458.0 (ChemBioDraw), found 458.2. IR (cm
-1
): 3061 (aromatics, C-H), 1724 
(C=O), 1638, 1617 (C=C), 1191 (C-O), 983 (=C-H), 750 (C-Cl). 
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 Figure 5.7  
1
H NMR of perphenazine-acrylate.  
 
Figure 5.8 
13
C NMR of perhenazine-acrylate. 
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Polyethyleneimine-Perphenazine Conjugates (PEI-P): The PEI-P conjugates were 
synthesized via Michael addition reaction of PEI and perphenazine-acrylate. To a solution of PEI 
(40 mg, 0.067 mmol) in 3 mL chloroform in three flat bottoles were added perphenazine-acrylate 
(45.8 mg, 0.1 mmol; 91.6 mg, 0.2 mmol; 137.4 mg, 0.3 mmol) dropwise by syringe over 10 min, 
respectively. The above mixture was stirred for 5 days. Then the solvent was removed through a 
rotavapor under reduced vacuum and dried under a high vacuum system to yield sticky yellowish 
oil, PEI-P-1.5 (85 mg, ~100%), PEI-P-3.0 (131 mg, ~100%), and PEI-P-4.5 (177 mg, ~100%) 
1
H 
NMR of PEI-P-4.5 (500 MHz, CDCl3) δ 7.11~6.81 (Benzene ring of perphenazine), 4.15, 3.85 
(Benzene-NCH2, COO-CH2), 2.83-2.40 (PEI-NHCH2CH2COO, PEI-NHCH2CH2COO, PEI-
NCH2CH2COO, CH2 of piperazin, piperazin-CH2 CH2 of PEI), 1.89 (br, piperazin-
CH2CH2CH2N); 
13
C NMR of PEI-P-4.5 (500 MHz, CDCl3) δ 172.6, 146.8, 144.6, 133.4, 128.1, 
127.7, 127.6, 124.9, 123.7, 123.1, 122.4, 116.0, 62.0, 59.4, 57.9, 56.8, 55.7, 53.7, 53.6, 53.4, 53.1, 
45.5, 24.5; IR (cm
-1
): 3345 (NH, NH2) 3061 (aromatics, C-H) 1730 (C=O), 1214 (C-O-C), 1103 
(C-N), 983 (=C-H). 750 (C-Cl). In the meantime, the absence of bands at 1638, 1617 and 983 
cm
-1
, which corresponding to C=C stretching vibration, demonstrated the successful Michel-
Addition reaction of perophenazine-acrylate and PEI. 
Perphenazine Loading = (integral of Ar-H in perphenazine/7)/(integral of CH2 in PEI/4) 
Perphenazine Loading = (integral of Ar-H in perphenazine/7)/{[all integral of CH2- integral of 
(d-g, i, j)]/4} 
Perphenazine Loading of PEI-P-1.5 = (7/7)/{[59.53 - 12 - 4 × (7/7)]/4} = 9.2% 
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Perphenazine Loading of PEI-P-3.0 = (7/7)/{[36.32 - 12 - 4 × (7/7)]/4} = 19.7% 
Perphenazine Loading of PEI-P-4.5 = (7/7)/{[28.08 - 12 - 4 × (7/7)]/4} = 33.1% 
NMR results show that there are 1.5 perphenazine molecules per PEI chain for PEI-P-1.5, 3.0 
perphenazine molecules per PEI chain for PEI-P-3.0 and 4.5 perphenazine molecules per PEI 
chain for PEI-P-4.5.  
 
Figure 5.9 
1
H NMR spectrum of PEI-P-1.5. 
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Figure 5.10 
1
H NMR spectrum of PEI-P-3.0. 
 
Figure 5.11 
1
H NMR spectrum of PEI-P-4.5. 
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Chapter 6: Detoxification of A Peptide by Polymeric Conjugates 
6.1 Introduction 
Synthetic modulators that manipulate amyloid aggregation have shown promise in 
therapeutic application for these amyloid related diseases, but eventually failed in clinical trials.
1
 
The reason is that most of the previous therapeutic strategies were based on simple inhibition of 
amyloid aggregation, and these strategies were not designed to directly target toxic amyloid 
oligomers.
2
 It has been shown that oligomeric forms of A are potent neurotoxins that play a 
major role in neurodegeneration.
3
 In our systems, beyond simple modulation of amyloid 
aggregation, mP-iAconjugates specifically stabilize amyloid oligomers and convert the 
oligomers into less toxic nanospheroid structures; PEI-P conjugates shorten the presence time of 
toxic oligomers by accelerating the intermediates formation.  
In the previous studies, Stroud and coworkers studied the structure-toxicity relationship 
of the fibrillar oligomers.
4
 The fibrillar oligomers were prepared in dilute ammonium hydroxide 
and the size were characterized by TEM and SEC. MTT cell viability assays showed that fibrillar 
oligomers are toxic to HeLa cells and PC-12 neuronal cells at concentrations as low as 2.25 
μg/mL (0.5 μM of A42 monomer equivalent). To determine the structure of the fibrillar 
oligomers, Stroud and coworkers performed CD and X-ray powder diffraction. The results 
demonstrated that the fibrillar oligomers have fiber like cross- structures with antiparallel -
sheet. Further modeling studies showed that cross- structures are related to greater curvature 
and increasingly large holes in the oligomers, suggesting that the toxicity may be related to the 
potential for oligomers to form pores. Pore formation has been implicated in the toxicity of A 
oligomers. 
In this Chapter, we investigate the detoxification of Aby mP-iAand PEI-P conjugates. 
Circular dichroism (CD) studies show that the A intermediates stabilized by polymeric 
conjugates preserve non -sheet secondary structures. MTT cell viability assays demonstrate that 
the polymeric conjugates efficiently detoxify At remains to be seen if the detoxification effect 
results from the non -sheet secondary structures of Aintermediates. 
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6.2 Secondary Structures of A Nanostructures Stabilized by mP-iA5 Conjugates 
In Chapter 3, we have demonstrated that mP-iA5 conjugates stabilized A40into 
uniform nanostructures. Here, we used CD to study the secondary structure
5
 of nanostructure 
stabilized by mP-iA5 conjugates. Initially, the CD spectrum of A40 (15 μM) aggregation 
typically displays a curve with a negative peak at 198 nm, which is characteristic of random 
coils.
6
 As A40 continues to aggregate, the negative peak at 198 nm was converted to the positive 
peak around 194 nm and a negative peak around 217 nm. The change of the CD spectra indicates 
the conformational conversion of A40 from random coils to -sheets, and thus suggests the 
formation of A40 fibrils.  
The CD studies showed that the negative peaks at 198 nm stayed unchanged with 1 equiv 
of mP-iA5-7% conjugates (Figure 6.1), which demonstrated that the spherical nanostructure 
stabilized by mP-iA5-7% conjugates preserved random coil structure. As control, figure shows 
the β-sheet formation in the CD spectra in the presence of 21 equiv of iA5. These results 
validate the ThT assays and AFM studies described in Chapter 3 and demonstrate the inhibitory 
effects of mP-iA5-7% conjugates on A40 aggregation. The CD results demonstrate that A40 
complex stabilized by mP-iA5-7% conjugates remained random coil structures, but not the -
structured oligomers which proved to be toxic in the previous literatures.  
 
Figure 6.1 CD spectra. Fibrillation kinetics of A40 (15 M) monitored by CD without 
modulators (a), and with 15 M of mP-iA5-7% conjugates, 1.0 equiv (b), and 315 M of iA5, 
21 equiv (c). CD measurements were performed after 0 and 24 h incubation of A40 in PBS 
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Figure 6.1 (cont.) buﬀer (pH 7.4) with continuous shaking (567 rpm) at 37 °C. We define equiv 
as the molar ratio of mP-iA5-7% conjugates and iA5 to A40. 
6.3 Detoxification Effect of mP-iA5 Conjugates on A Oligomers 
To examine the effect of mP-iA5 conjugates on toxicity of A40 towards cells, we used 
MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) cell viability assays. We 
first incubated PC-12 cells with control polymer, free peptide iA5, or mP-iA5 conjugates alone 
to evaluate the cytotoxicity of modulators themselves. MTT results proved that the control 
polymer, iA5, and conjugates were non-toxic (Figure 6.2).  
 
Figure 6.2 Toxicity of control polymer, iA5, and mP-iA5 conjugates towards PC-12 cells. The 
cell survival of the PBS controls is taken to be 100%. Error bars correspond to standard 
deviations of six sets of experiments. 
To study the detoxification effect of modulators, A40 (5 M) was incubated with or 
without mP-iA5 conjugates to allow prefibrillar A40 oligomers to form, and the morphologies 
were confirmed by TEM. Then the preincubated oligomers were added to the pre-seeded cells at 
a final concentration of 0.5 M and incubated for another 24 h. The cell viability by the end of 
24 h was determined by MTT assays. The sample preparation and procedure are summarized in 
Figure 6.3. 
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Figure 6.3 Sample preparation and procedure for MTT assays.  
The MTT assay shows that the pre-incubated A40 alone kills 60% of the PC-12 cells, 
relative to the control in which the cells are only incubated with PBS buffer solution (Figure 6.4). 
The cell viability was not significantly changed when A40 was co-incubated with control 
polymer or free peptide iA5, which indicated that control polymer and iA5 have no 
detoxification effect (Figure 6.4b). However, when A40 was pre-incubated in the presence of 5 
equiv of mP-iA5-12% and 0.5 equiv of mP-iA5-12%, the cell viability of PC-12 cells was 
increased by 60% and 49% respecively. In the presence of 5 equiv of mP-iA5-7% and 0.5 equiv 
of mP-iA5-7%, the cell viability of PC-12 cells was increased by 60% and 35% respecively. In 
the presence of 5 equiv of mP-iA5-3% and 0.5 equiv of mP-iA5-3%, the cell viability of PC-12 
cells was increased by 58% and 47% respecively (Figure 6.4a). This result indicates that mP-
iA5 conjugates have the ability to attenuate cytotoxicity caused by A40 aggregation. The MTT 
assay also shows that mP-iA5 conjugates at 0.1 equiv have no significant detoxification effect 
on the A40 aggregates, indicating that the mP-iA5 conjugates reduce toxcity of A40 in a dose-
dependent manner.  
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Figure 6.4 Detoxification of A40 aggregates by mP-iA5 conjugates (a), and control polymer or 
iA5 (b). Pre-incubated A40 samples with and without conjugates were added to the culture 
medium of differentiated PC-12 cells. (Final A40 concentration is 0.5 M.) Cell viabilities were 
measured after incubation for 24 h using MTT assays. The cell survival of the PBS control is 
taken to be 100%. Error bars correspond to standard deviations of six sets of experiments. We 
define equiv as the molar ratio of mP-iA5 conjugates to A40. 
6.4 Secondary Structures of A Intermediates Stabilized by PEI-P Conjugates 
In Chapter 5, we have demonstrated that PEI-P conjugates have a dual modulatory effect 
on A40 aggregation. To further investigate the effects of the PEI, perphenazine, and PEI-P-4.5 
on the early transition of A40 aggregation, we turned to CD studies which are extensively used 
to probe secondary structures of polypeptides and provide a means to monitor the structural 
conversion over a period of time.
5
  
When A40 was incubated to aggregate, we intentionally reduced the intensity of shaking 
(from 567 rpm for ThT assays to 100 rpm for CD) to increase the lag phase, so that we could 
better observe the effects of those modulators on the early stage of A40 aggregation. Initially, 
the CD spectrum of A40 (50 μM) aggregation typically displays a curve with a negative peak at 
198 nm, which is characteristic of random coils. As A40 continues to aggregate, the intensity of 
the negative peak at 198 nm gradually diminishes over 45 h, and a new curve forms with a 
positive peak emerging around 194 nm and a negative peak around 217 nm (Figure 6.5a). The 
change of the CD spectra indicates the conformational conversion of A40 from random coils to 
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-sheets, and thus suggests the formation of A40 fibrils. Our CD results are consistent with 
those reported in literature.
6
  
The CD studies show that the negative peaks at 198 nm disappear after 4 h incubation of 
A40 with 1.3 equiv of PEI (Figure 6.5b) and PEI-P (Figure 6.5c), while the peak stays 
unchanged with 6 equiv of perphenazine (Figure 6.5d). These CD results demonstrate that the 
structural changes of A40 are expedited by PEI and PEI-P-4.5, while hindered by perphenazine. 
In addition, Figures 6.5c-d show that no peaks corresponding to the β-sheet formation appear in 
the CD spectra after 45 h incubation, suggesting the absence of mature fibrils. These results 
validate the ThT assays and AFM studies described above, and demonstrate the inhibitory effects 
of PEI-P-4.5 and perphenazine on A40 aggregation. The CD results over time (Figure 6.5c) 
support that PEI-P-4.5 is able to promote the early structural transformation during A40 
aggregation and inhibit fibrillation. PEI accelerates A aggregation but shows weak -sheet 
characteristics on CD spectrum (Figure 6.5b), which is consistent with AFM studies. AFM 
images indicate that PEI redirects A40 aggregation to form disordered aggregates without 
perfect -sheet structures.  
 
Figure 6.5 CD spectra. Fibrillation kinetics of A40 (50 M) monitored by CD without 
modulators (a), and with 65 M of PEI, 1.3 equiv (b), 65 M of PEI-P-4.5, 1.3 equiv (c), and 
300 M of perphenazine, 6 equiv (d). CD measurements were performed after 0, 4, 8, 22, and 45 
h incubation of A40 (50 M ) in the absence and presence of PEI, perphenazine, or PEI-P-4.5 in  
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Figure 6.5 (cont.) a 10 mM sodium phosphate buﬀer (pH 7.4) with continuous shaking (100 rpm) 
at 37 °C. We define equiv as the molar ratio of PEI oligomer, perphenazine or PEI-P-4.5 
oligomer to A40. 
6.5 Detoxification Effect of mP-iA5 Conjugates on A Aggregates  
We used MTT cell viability assays to examine the effect of the PEI-P conjugates on 
toxicity of A40 towards cells. We first incubated PC-12 cells with PEI and PEI-P conjugates 
alone to evaluate the cytotoxicity of modulators themselves. MTT results proved that PEI and 
PEI-P conjugates were non-toxic (Figure 6.6).  
As control, we incubated A40 without PEI, perphenazine and PEI-P conjugates to allow 
prefibrillar A40 aggregates to form. The MTT assay shows that the pre-incubated A40 alone 
kills 60% of the PC-12 cells, relative to control in which the cells are only incubated with 
HEPES buffer solution (Figure 6.7). The deaths of PC-12 cells incubated with 1 equiv and 0.1 
equiv of PEI are 40% and 55%, respectively, which indicates the low detoxification of A40 by 
PEI. However, the death of PC-12 cells drops to 15%, 26% and 21%, respecively when A40 was  
 
Figure 6.6. Toxicity of PEI and PEI-P conjugates towards PC-12 cells. The cell survival of the 
HEPES controls is taken to be 100%. Error bars correspond to standard deviations of six sets of 
experiments. 
pre-incubated in the presence of PEI-P-1.5, PEI-P-3.0 and PEI-P-4.5 (1.0 equiv). This result 
indicates that the PEI-P conjugates have the ability to attenuate cytotoxicity caused by A40 
aggregation, and the detoxicification effects do not have significant difference between three 
139 
 
conjugates. The MTT assay also shows that the PEI-P conjugates at 0.1 equiv only slightly 
detoxify the A40 aggregates, indicating that the PEI-P conjugates reduce toxcity of A40 in a 
dose-dependent manner. 
 
 
Figure 6.7 Detoxification of A40 aggregates by PEI and PEI-P conjugates. PEI and PEI-P 
conjugates reduce A40 cytotoxicity towards PC-12 cells at different concentrations. Pre-
incubated A40 samples with and without PEI or PEI-P conjugates were added to the culture 
medium of differentiated PC-12 cells. (Final A40 concentration is 0.5 M.) Cell viabilities were 
measured after incubation for 24 h using MTT assays. The cell survival of the HEPES control is 
taken to be 100%. Error bars correspond to standard deviations of six sets of experiments. We 
define equiv as the molar ratio of PEI-P-1.5 oligomer, PEI-P-3.0 oligomer or PEI-P-4.5 
oligomer to A40 (Results from t test, *p < 1 × 10
−3
; **p < 1 × 10
−4
). 
6.6 Experimental Details 
6.6.1 Circular Dichroism Spectroscopy 
Circular Dichroism (CD) spectroscopy. CD spectra of A40 solution incubated without or with 
modulators were recorded in a JASCO J-815 Spectrometer (JASCO Co., Tokyo, Japan), using a 
quartz cuvette (1 mm path length). The spectra were taken as the average of three accumulations 
from 190 and 260 nm at a speed of 50 nm/min. All of the samples were incubated at 37 °C in 10 
mM phosphate buffer solution (PBS) with a continuous agitation speed of 100 rpm for different 
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time intervals before analyses. Spectra were calibrated by subtracting the buffer or sample 
solution baseline. 
6.6.2 Methyl Tetrazolium Assays 
Cell cultures. PC-12 cells (a cell line derived from a pheochromocytoma of the rat adrenal 
medulla, ATCC) were cultured in F-12K supplied with 15% horse serum, 2.5% fetal bovine 
serum and antibiotics (50 units mL
-1
 penicillin and 50 units mL
-1
 streptomycin) at 37 

C in a 
humidiﬁed atmosphere containing 5% CO2. 
Toxicity of modulators towards PC-12 cells. PC-12 cells were seeded into 96-well plates at an 
initial seeding density of 1.0 × 10
4
 cells/well in 90 L medium. Then, the cells were cultured for 
20 h at 37 °C in 5% CO2 before the samples were added. The modulators (10 L per well) were 
added to each well containing medium. After incubated for 24 h, the MTT solution (15 L) was 
added to each well and incubation continued for additional 4 h at 37 °C in 5% CO2. Then the 
solubilization Solution/Stop Mix (100 L) was then added to each well. After incubation for 
additional 2 h at 37 °C, the absorbance was measured at 570 nm. The background absorbance 
was recorded at 700 nm. Each of the samples was repeated with 6 replicates. The results were 
normalized by setting the cell survival of PC-12 cells in the buffer controls to be 100%. 
Detoxification of A40. PC-12 cells were plated out at 1.0 × 10
4
 cells/well in 96-well plates. The 
cells were cultured 24 h at 37 °C in 5% CO2 before adding samples. Aβ40 monomers without and 
with modulators were incubated at 37 °C with shaking prior to the addition to the cells. 10 L of 
preincubated Aβ40 without and with modulators were added (The final concentration of the 
preincubated A40 solutions is 0.5 M.). The resulting mixtures were incubated for additional 24 
h at 37 °C in 5% CO2. The absorbance was then measured at 570 nm. The background 
absorbance was recorded at 700 nm. Each of the samples was repeated with 6 replicates. The 
results were normalized by setting the cell survival of the buffer controls to be 100%. 
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